Search

Your search keyword '"M Nishino"' showing total 1,293 results
Start Over Author "M Nishino"
1,293 results on '"M Nishino"'

1. A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities

Author

M. Moll, A.L. Peljto, J. Kim, H. Xu, C. Debban, X. Chen, A.A. Menon, R.K. Putman, A.J. Ghosh, A. Saferali, M. Nishino, H. Hatabu, B.D. Hobbs, J. Hecker, G. McDermott, J.A. Sparks, L.V. Wain, R. Allan, M.D. Tobin, B.A. Raby, S. Chun, E.K. Silverman, A.C. Zamora-Martinez, V.E. Ortega, C.K. Garcia, R.G. Barr, A. Manichaikul, J. Dupuis, G.T. O'Connor, T.E. Fingerlin, G.M. Hunninghake, D.A. Schwartz, and M.H. Cho

Published
2023
Full Text
View/download PDF

3. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting

Author

Tetsuya Matoba, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Yukihiro Koretsune, Takafumi Hiro, Tetsuya Sumiyoshi, Kazumi Kimura, Yoichiro Hashimoto, Teruyuki Hirano, Hiroyuki Daida, Yasushi Okada, Tsutomu Yamazaki, A. Nakamura, E. Tamiya, T. Yamamoto, S. Suetake, T. Noguchi, S. Nakamura, A. Matsumura, J. Kojima, S. Suwa, H. Yamaguchi, K. Kaikita, T. Yasu, A. Nakajima, T. Yamada, H. Arai, Y. Hata, T. Sakanashi, H. Tateishi, T. Nakayama, Y. Nozaki, M. Akao, Y. Okumura, M. Tokue, N. Kuroki, Y. Maruyama, T. Matoba, N. Hagiwara, H. Suzuki, Y. Nishida, M. Ajioka, K. Yumoto, S. Shimizu, T. Aoyama, H. Shimomura, T. Takeda, K. Oshiro, N. Sugishita, Y. Shibata, T. Otonari, H. Kihara, H. Ogawa, A. Ohno, M. Hazama, M. Shimizu, K. Tsukahara, S. Haruta, T. Wakeyama, T. Haruna, M. Ito, K. Fujii, N. Atsuchi, M. Sata, K. Kimura, N. Hasebe, Y. Kobayasi, K. Ohsato, K. Hironaga, Y. Naganuma, K. Anzaki, K. Oiwa, S. Okazaki, Y. Nakagawa, K. Tokuhiro, K. Tanaka, T. Momose, Y. Fukushima, R. Kametani, K. Kawamitsu, Y. Saito, S. Akashi, K. Kumagai, K. Eshima, T. Tobaru, T. Seo, K. Okuhara, K. Kozuma, Y. Ikari, T. Takahashi, I. Michishita, H. Fujikura, S. Momomura, Y. Yamamoto, K. Otomo, T. Matsubara, H. Tashiro, T. Inoue, M. Ishihara, I. Shiojima, E. Tachibana, J. Ako, K. Sumii, N. Yamamoto, N. Ohmura, T. Nakamura, Y. Morita, N. Takahashi, K. Watanabe, H. Fujinaga, M. Maruyama, T. Oka, T. Shirayama, T. Amano, K. Fukui, K. Ando, S. Oshima, S. Kagiyama, H. Teragawa, M. Yuge, S. Ono, T. Koga, K. Fujiu, M. Kuwabara, Y. Ohya, Y. Yumoto, N. Kuji, M. Ikemura, K. Kario, K. Chatani, K. Sato, H. Miyagi, M. Murakami, K. Saito, M. Hoshiga, S. Sato, N. Kubo, Y. Sakamoto, K. Ashida, H. Sakamoto, S. Murasaki, H. Uehara, T. Akasaka, Y. Ooba, S. Nakahara, Y. Hanaoka, T. Nishimiya, R. Tsunoda, Y. Onuma, S. Higuchi, A. Tani, A. Wada, M. Kato, H. Obata, Y. Higuchi, T. Endo, R. Katou, T. Matsunaga, T. Matsuoka, H. Noguchi, M. Usui, T. Hayashi, Y. Otsuji, T. Osaki, H. Zaizen, H. Yoshihara, K. Kadota, T. Hirose, T. Miyazawa, A. Mori, M. Takano, W. Shimizu, M. Wake, S. Oriso, M. Yoshiyama, S. Kakinoki, T. Nishioka, T. Ozaki, K. Nomoto, K. Seki, K. Kawai, Y. Ozaki, S. Miura, M. Kawasaki, R. Funada, K. Dote, T. Nagano, S. Okamoto, T. Kubo, Y. Murozono, T. Owada, T. Doke, T. Matsumura, M. Horiuchi, A. Takaishi, M. Yamamoto, H. Nakashima, M. Munemasa, Y. Sakata, N. Inoue, T. Ota, Y. Hamano, N. Abe, T. Tsubokura, M. Goto, I. Kubota, M. Yano, K. Umetani, T. Date, H. Morimoto, T. Noda, S. Goto, K. Hibi, A. Nakano, S. Hiramitsu, Y. Kihara, M. Sugi, N. Shiba, D. Izumi, T. Sato, S. Tayama, T. Matsui, A. Suzuki, K. Ajiki, M. Oishi, M. Kiryu, T. Ko, H. Ando, S. Miyazaki, T. Kinugawa, H. Otake, H. Kitaoka, Y. Hirata, S. Honda, M. Manita, Y. Ishii, H. Oka, Y. Nanba, M. Nishino, T. Sakamoto, T. Saito, H. Sakai, M. Ichikawa, S. Namiuchi, K. Inoue, N. Komiyama, Y. Akashi, Y. Nakamura, T. Komaru, T. Hosokawa, T. Chikamori, H. Tanaka, O. Arasaki, K. Aonuma, Y. Wakasa, T. Yoshizawa, T. Sugano, N. Yokota, A. Kakutani, T. Suzuki, Y. Abe, T. Kataoka, H. Okayama, H. Yokoi, K. Chin, K. Hasegawa, H. Tomita, H. Honzyo, H. Kawai, K. Yamamoto, Y. Morino, S. Tsujiyama, S. Hamasaki, Y. Niijima, Y. Mizuno, A. Maki, K. Tanabe, T. Murohara, S. Naomi, M. Arikawa, T. Kato, N. Matsumoto, T. Minamino, H. Sairenji, N. Miyamoto, H. Ito, Y. Matsuura, S. Hata, Y. Nakatsu, T. Onodera, M. Yoshimura, H. Amano, E. Tokutake, M. Kasao, M. Moriguchi, M. Tsuji, H. Yamamoto, Y. Yanbe, T. Iwasawa, M. Suzuki, and H. Mori

Subjects
Rivaroxaban, medicine.medical_specialty, business.industry, Unstable angina, medicine.medical_treatment, Percutaneous coronary intervention, Atrial fibrillation, medicine.disease, Thrombosis, Coronary artery disease, Internal medicine, medicine, Cardiology, cardiovascular diseases, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, Stroke, medicine.drug
Abstract

Objectives The aim of this AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial subgroup analysis was to examine rivaroxaban monotherapy benefits and their relation to the time between stenting and enrollment among patients after coronary stenting. Background Of 2,215 patients with atrial fibrillation and stable coronary artery disease in the AFIRE trial, rivaroxaban monotherapy was noninferior to rivaroxaban plus antiplatelet therapy (combination therapy) in terms of efficacy and superior for safety endpoints. However, thrombotic risk after antiplatelet therapy cessation remained a concern among 1,444 patients who had undergone coronary stenting >1 year before enrollment. Methods The benefits of rivaroxaban monotherapy in coronary stenting subgroups were assessed for efficacy (a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death of any cause), safety (major bleeding defined according to International Society on Thrombosis and Haemostasis criteria), ischemic endpoints, net adverse clinical event, and time between stenting and enrollment. Results Efficacy and safety endpoints for monotherapy were superior to combination therapy, with HRs of 0.70 for efficacy (95% CI: 0.50-0.98; P = 0.036) and 0.55 for safety (95% CI: 0.33-0.92; P = 0.019). For ischemic endpoints, the HR was 0.82 (95% CI: 0.58-1.15; P = 0.240). The HR became smaller with longer time between stenting and enrollment (efficacy, P for interaction = 0.158; safety, P = 0.097). Conclusions In patients with atrial fibrillation after coronary stenting, the benefits of rivaroxaban monotherapy for efficacy and safety endpoints were consistent with those in the whole AFIRE trial population. The benefits became apparent with longer time between stenting and enrollment. (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study [AFIRE]; UMIN000016612 , NCT02642419 )

Published
2021
Full Text
View/download PDF

6. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS

Author

B, Ricciuti, J V, Alessi, A, Elkrief, X, Wang, A, Cortellini, Y Y, Li, V R, Vaz, H, Gupta, F, Pecci, A, Barrichello, G, Lamberti, T, Nguyen, J, Lindsay, B, Sharma, K, Felt, S J, Rodig, M, Nishino, L M, Sholl, D A, Barbie, M V, Negrao, J, Zhang, A D, Cherniack, J V, Heymach, M, Meyerson, C, Ambrogio, P A, Jänne, K C, Arbour, D J, Pinato, F, Skoulidis, A J, Schoenfeld, M M, Awad, and J, Luo

Subjects
Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mutation, Programmed Cell Death 1 Receptor, Humans, Forkhead Transcription Factors, Genomics, B7-H1 Antigen
Abstract

Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASClinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype.Of 2327 patients with KRAS-mutated (KRASKRAS

Published
2022

7. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

Author

J.F. Gainor, H. Rizvi, E. Jimenez Aguilar, F. Skoulidis, B.Y. Yeap, J. Naidoo, S. Khosrowjerdi, M. Mooradian, C. Lydon, P. Illei, J. Zhang, R. Peterson, B. Ricciuti, M. Nishino, J.A. Roth, J. Grishman, D. Anderson, B.P. Little, B.W. Carter, K. Arbour, J.L. Sauter, M. Mino-Kenudson, J.V. Heymach, S. Digumarthy, A.T. Shaw, M.M. Awad, and M.D. Hellmann

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Programmed Cell Death 1 Receptor, Apoptosis, PD-L1 expression, NSCLC, tumor mutation burden, B7-H1 Antigen, Article, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Programmed cell death 1, Phospholipase D, Humans, Medicine, Lung cancer, Retrospective Studies, Smokers, biology, Antitumor immunity, business.industry, Hazard ratio, Hematology, medicine.disease, Blockade, PD-1 inhibitor, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Pd 1 blockade, Pd l1 expression, Non small cell, business
Abstract

Background: Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. Tumor mutation burden (TMB) also predicts response to ICIs but is often not available in real time for decision making in the first-line setting. Smoking exposure can be a proxy for TMB in NSCLC. The impact of smoking status on efficacy of PD-1 blockade in NSCLC patients with PD-L1 TPS ≥50% has not been well defined. Patients and methods: To investigate the relationship between smoking and activity of ICIs in NSCLC, we retrospectively studied 315 patients with NSCLC and PD-L1 TPS ≥50% at five USA academic medical centers. Objective response rates (ORRs), progression-free survival (PFS), and duration of response (DOR) were compared between never (10 pack-years) smokers. A subset of patients underwent next-generation sequencing to estimate TMB. Results: We identified 36 (11%) never, 42 (13%) light, and 237 (75%) heavy smokers with NSCLC and PD-L1 TPS ≥50% treated with ICIs. Objective responses were observed in 27%, 40%, and 40% of never, light, and heavy smokers, respectively (P = 0.180 never versus heavy; P = 1.000 light versus heavy). Median PFS and median DOR were numerically shorter in never and light smokers compared with heavy smokers (PFS 3.0 versus 4.0 versus 5.4 months; median DOR 6.9 versus 10.8 versus 17.8 months), but were not statistically different [PFS: hazard ratio (HR) 1.37, P = 0.135 and HR 1.24, P = 0.272; DOR: HR 1.92, P = 0.217 and HR 1.79, P = 0.141]. Conclusions: PD-(L)1 inhibitors are associated with antitumor activity in NSCLC with PD-L1 TPS ≥50% regardless of smoking status. Nevertheless, there is a signal of potentially decreased durability among never and light smokers that should be further evaluated. Distinct immunobiologic features may affect initial response versus durability of antitumor immunity to programmed cell death 1 (PD-1) blockade.

Published
2020
Full Text
View/download PDF

8. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Author

B. Ricciuti, J.V. Alessi, A. Elkrief, X. Wang, A. Cortellini, Y.Y. Li, V.R. Vaz, H. Gupta, F. Pecci, A. Barrichello, G. Lamberti, T. Nguyen, J. Lindsay, B. Sharma, K. Felt, S.J. Rodig, M. Nishino, L.M. Sholl, D.A. Barbie, M.V. Negrao, J. Zhang, A.D. Cherniack, J.V. Heymach, M. Meyerson, C. Ambrogio, P.A. Jänne, K.C. Arbour, D.J. Pinato, F. Skoulidis, A.J. Schoenfeld, M.M. Awad, and J. Luo

Subjects
G12D, KRAS, NSCLC, PD-(L)1 blockade, Oncology, Hematology
Published
2022

9. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial

Author

M Nishino, T Shinozaki, J Lash, N Takahashi, H Kokane, Béla Merkely, F Guimaraes, T Arakawa, C Zaidman, V Bugan, A Arouni, D Precoma, L Ermoshkina, A Pandey, D Kucera, I Efremov, L Younis, H Nagashima, C Chiang, M Ogunniyi, R Nilk, D Wang, T Haddad, M Zacharias, R Nischik, S Leslie, Mikhail Kosiborod, J Castriz, K Saito, I Weigmann, A Schabauer, A Kiyosue, M Hernandes, Charlotta Ljungman, Subodh Verma, Marc S. Sabatine, Y Khaykin, C Ince, S Iskander, Mark C. Petrie, G Drelich, R Lee, J Slaby, A Nikfarjam, M Kanwar, R Smik, Y Onishi, M Gadkari, M Suzuki, A Viera, S Matsuoka, F Poór, K Egstrup, M Bennett, Y Gu, L Maia, T Lewis, D Sinha, Jonathan G. Howlett, Andrej Dukát, J Shih, L Wu, O Montaña, D Peng, V Mehta, S Higashiue, S Rassi, Junbo Ge, S Mansour, H Nguyen, J Dong, E O’Meara, S Joseph, G Cursack, L Køber, G Reis, A Naik, M Schou, R Ahuad Guerrero, V Kostenko, Silvio E. Inzucchi, Scott D. Solomon, R Robles De Medina, E Vishneva, Y Didenko, D García Brasca, A Sosa Liprandi, M Bernstein, A Hedman, K Kuwahara, A Hirohata, Y Li, Michael Böhm, D Karageorgiev, B Al-Joundi, Jan Belohlavek, P Hajek, E Noori, J Spinar, S Sinha, M Milanova, B Groenemeijer, T Hashimoto, M Najenson, M Higuchi, C Brown, V Macek, S Mahal, B Merkely, K Lindmark, F Nasser-Sharif, N Botushanov, A Costard-Jäckle, S Hiroi, D Raev, L Lin, S Suzuki, N Toursarkissian, Rudolf A. de Boer, J Hove, W Huang, O Akinboboye, T Kadokami, Y Ivanova, N Koziolova, L Kantaros, L Pawłowicz, R Kuchar, K Chang, G Hamroff, C Staniloae, K Appel, L Spinarova, N Runev, J Lampart, N Jaffrani, Dapa-Hf Investigators, S Emani, L Antalik, Y Okumura, A Pereira, K Fujii, Y Hisamatsu, N Iliev, M Sandhu, S Vizel, M Pursley, Y Momiyama, A Ezhov, R Sawant, Z Zheng, M Hominal, S Mehta, B Han, K Shah, R Ściborski, J Saraiva, R Kawamura, R Witek, A Wada, C Majul, U Stephan, L Fu, David L. DeMets, M Tokmakova, D Martinez, L Jamriskova, Tzvetana Katova, E Schmidt, X Li, Eileen O'Meara, O Mayer, W Tseng, K Fujimoto, L Bellersen, C Wu, A Japp, J Sala, Mirta Diez, F Arantes, Kieran F. Docherty, Anna Maria Langkilde, R Cheng, H Chang, M Böhm, J Londono, J Walsh, Chern-En Chiang, R Mariankowski, A Mihov, Colin J. Petrie, M Mahapekar, Y Noguchi, Y Yasaka, Robert S. McKelvie, J Albisu, D Gupta, K Seki, Pardeep S. Jhund, C Király, A Al-Zoebi, H Ueno, I Malek, M Jardula, A Kazakov, I Lieber, F Franchi, D Avino, S Pereiro Gonzalez, P Wakefield, P Pimentel, T Kasai, E Fruehling, Olof Bengtsson, P Kopylov, S Uchikawa, X Guo, J Borges, S Tereschenko, F Azzari, J Selecky, S Sassone, J Vyselaar, S Lederman, J Howlett, Committees, E Vasconcellos, J Kostis, A Czigány, G Masszi, J Izzo, Z Járai, F Neuenschwander, L Tomasova, Mikaela Sjöstrand, C De Nooijer, Felipe Martinez, H Tsutsui, I Uchida, J Patel, A Arif, W Takahashi, M Nassif, K Moritani, M Mohri, J Shilko, Tereshchenko Sn, B Paolino, Z Wang, S Tanaka, João Pedro Ferreira, Y Takagi, H Jiang, A Maltcev, Piotr Ponikowski, V Bhargava, N Komiyama, W Dong, S Verma, S Weiss, L Busak, R Sotolongo, B Foley, C Hsia, John J.V. McMurray, T Mooe, R Gardner, N Cluigt, H Swart, N Spasova, Clare Murphy, K Harada, S Srivastava, P Olexa, B Bertolet, P Andrássy, M Petrie, Inder S. Anand, L Levinson, D Rupka, N Fujimoto, S Aksentiev, Y Hata, L Krylova, N Dzhaiani, R Korzeniak, T.Z. Maung, G Hickey, F Colombo Berra, X Zhang, Q Zhao, B Chompalova, D Avramov, M Asakura, A Hershson, G Mercau, N Takeyasu, J Menon, D Pevzner, T Nunohiro, T Katova, F Syed, W French, P Rossi, C Constance, Z Paltsman, K Tsukahara, A Gogov, M Liu, K Ilieva, I Majercak, Y Zhou, Vijay K. Chopra, T Anzai, F Mody, P Jhund, V Kothiwale, M Hartleib, S Zoet Nugteren, Z Li, J Drożdż, E Krcova, Lars Køber, A Galyavich, A Dincheva, R García Durán, D Hotchkiss, V Chopra, R Manshadi, T Greene, J Taborda, A Fernandez, E Lo, Pham Nguyen Vinh, G Gislason, K Sumii, G Lewis, L Nagy, S Genth-Zotz, J Liu, A Clark, P Leaes, A Wilke, Y Hayashi, J Belohlavek, Y Liang, S Szynal, M Van Hessen, T Kakuta, T Dalcoquio, J Skopek, S Karna, Q Tang, R Vijayaraghavan, K Fukui, X Lin, J Teel, S Nani, P Liu, D Vinanska, C Ljungman, Morten Schou, P Fulop, Y Katayama, D Song, L Yao, A Kimura, M Babapulle, D Kollarova, D Ho, E Fairman, S Deleon, V Pham, C Lindholm, T Kuramochi, S Boldueva, T Cimato, Y Ueda, T Shibasaki, H Takase, S Inoue, E MirekBryniarska, J Huang, D Aizenberg, R Chehayeb, J Van Eck, Y Pesant, Brian Claggett, H Do, I Hsieh, B Mikłaszewicz, R De Boer, Y Tomobuchi, J Carda, P Fong, N Kazemi, E Manenti, Y Komura, D Singal, Jarosław Drożdż, J Cha, T Nguyen, M Berk, E Hattori, B Kolomanov, Á Motyovszki, P Miękus, V Florea, T Lin, H Meno, G Simonis, L Videbæk, Y Dong, P Poirier, C Venugopal, D Tschöpe, M Deshpande, M Kellerer, L Chandra, K Ramanathan, C Lang, D Phaneuf, S Vladeva, H Kamiya, J Javier, Masahumi Kitakaze, M Talavera, Jose C. Nicolau, J Prokopczuk, B Truong, E Perna, W Sudnik, A Paraschos, H Sugino, S Banerjee, Akshay S. Desai, A Chernyavsky, H Luquez, P Nierop, P Udgire, G Caruso, M Slovenska, and H Iseki

Subjects
Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Placebo, Global Health, Ventricular Function, Left, law.invention, chemistry.chemical_compound, Randomized controlled trial, Double-Blind Method, Glucosides, law, Internal medicine, Cause of Death, medicine, Humans, Prospective Studies, Dapagliflozin, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Original Investigation, Aged, Heart Failure, Ejection fraction, Dose-Response Relationship, Drug, business.industry, Stroke Volume, Middle Aged, medicine.disease, New York Heart Association Functional Classification, Clinical trial, Survival Rate, chemistry, Intravenous therapy, Heart failure, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract

Importance: Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug to patients. Objective: To estimate the projected long-term treatment effects of dapagliflozin in patients with HFrEF over the duration of a patient’s lifetime. Design, Setting, and Participants: Exploratory analysis was performed of Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), a phase 3 randomized, placebo-controlled clinical trial conducted at 410 sites in 20 countries. Patients with an ejection fraction less than or equal to 40% in New York Heart Association functional classification II to IV and elevated plasma levels of N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Mean (SD) duration of follow-up was 17.6 (5.2) months. Interventions: Dapagliflozin, 10 mg, once daily vs placebo in addition to standard therapy. Main Outcomes and Measures: The primary composite outcome was time to first hospitalization for heart failure, urgent heart failure visit requiring intravenous therapy, or cardiovascular death. The trial results were extrapolated to estimate the projected long-term treatment effects of dapagliflozin over the duration of a patient’s lifetime for the primary outcome and the secondary outcome of death from any cause. Results: A total of 4744 patients (1109 women [23.4%]; 3635 men [76.6%]) were randomized in DAPA-HF, with a mean (SD) age of 66.3 (10.9) years. The extrapolated mean event-free survival for an individual aged 65 years from a primary composite end point event was 6.2 years for placebo and 8.3 years for dapagliflozin, representing an event-free survival time gain of 2.1 years (95% CI, 0.8-3.3 years; P = .002). When considering death from any cause, mean extrapolated life expectancy for an individual aged 65 years was 9.1 years for placebo and 10.8 years for dapagliflozin, with a gain in survival of 1.7 years (95% CI, 0.1-3.3; P = .03) with dapagliflozin. Similar results were seen when extrapolated across the age range studied. In analyses of subgroups of patients in DAPA-HF, consistent benefits were seen with dapagliflozin on both event-free and overall survival. Conclusions and Relevance: These findings indicate that dapagliflozin provides clinically meaningful gains in extrapolated event-free and overall survival. These findings may be helpful in communicating the benefits of this treatment to patients with HFrEF. Trial registration: ClinicalTrials.gov Identifier: NCT03036124.

Published
2021

10. A commercial radio receiver for lower ionosphere monitoring: Initial results

Author

N. J. Schuch, M. R. da Silva, D. B. Contreira, K. Nozaki, M. A. Abdu, E. R. de Paula, M. Nishino, K. Makita, C. G. M. Brum, and F. S. Rodrigues

Subjects
Ionosphere, absorption, fading, Geophysics. Cosmic physics, QC801-809
Abstract

A commercial computer controlled radio receiver has been used to measure signal strength of High Frequency (HF) signals in order to study the effects of geophysical events on radio communications and to test the system for ionospheric monitoring. The system was installed at the Southern Space Observatory (OES/CRSPE/INPE) in São Martinho da Serra, Brazil (29.43°S, 53.8°W, B = 23350 nT). Initial results show that this system is able to detect ionospheric radio absorption events. The commercial radio receiver has a computer serial interface, to control the reception frequency in order to acquire the values of the received signal strength. We describe the system and some initial results on radio absorption events associated to C and M classes of x-ray solar flares. The results suggest the possibility of using this low-cost system to study the daily variation of the lower ionosphere ionization and to study events of ionospheric absorption. Long period measurements give statistical information about the magnitude and time scale of fading, that can be used for planning radio links.

Published
2004

11. A commercial radio receiver for lower ionosphere monitoring: Initial results

Author

F. S. Rodrigues, C. G. M. Brum, K. Makita, M. Nishino, E. R. de Paula, M. A. Abdu, K. Nozaki, D. B. Contreira, M. R. da Silva, and N. J. Schuch

Subjects
absorción, desvanecimiento, ionosfera, Geophysics. Cosmic physics, QC801-809
Abstract

A commercial computer controlled radio receiver has been used to measure signal strength of High Frequency (HF) signals in order to study the effects of geophysical events on radio communications and to test the system for ionospheric monitoring. The system was installed at the Southern Space Observatory (OES/CRSPE/INPE) in Sāo Martinho da Serra, Brazil (29.43°S, 53.8°W, B = 23350 nT). Initial results show that this system is able to detect ionospheric radio absorption events. The commercial radio receiver has a computer serial interface, to control the reception frequency in order to acquire the values of the received signal strength. We describe the system and some initial results on radio absorption events associated to C and M classes of x-ray solar flares. The results suggest the possibility of using this low-cost system to study the daily variation of the lower ionosphere ionization and to stuy events of ionospheric absorption. Long period measurements give statistical information about the magnitude and time scale of fading, that can be used for planning radio links. doi: sin doi

Published
2004
Full Text
View/download PDF

12. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer

Author

A. Mizukami, A. Sakai, S. Sugimoto, F. Arihara, M. Matsuda, Y. Horita, A. Kida, M. Yano, K. Matsuda, and M. Nishino

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Paclitaxel, Receptor, ErbB-2, Drug Administration Schedule, Metastatic gastric cancer, 03 medical and health sciences, 0302 clinical medicine, Second line, Stomach Neoplasms, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Neoplasm Metastasis, Infusions, Intravenous, skin and connective tissue diseases, neoplasms, Aged, Aged, 80 and over, Pharmacology, business.industry, Weekly paclitaxel, Cancer, Hematology, Middle Aged, medicine.disease, Immunohistochemistry, Clinical trial, 030104 developmental biology, Fluorouracil, 030220 oncology & carcinogenesis, Female, business, medicine.drug
Abstract

Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy. We evaluated the efficacy and safety of weekly paclitaxel plus Tmab as second-line chemotherapy for HER2-positive gastric cancer patients.Eligible patients were older than or equal to 20 years, had histologically confirmed gastric adenocarcinoma that was HER2 positive (immunohistochemistry 3+ or immunohistochemistry 2+ and fluorescence in-situ hybridization positive or dual color in-situ hybridization positive), and had been treated previously with chemotherapy (pretreated or not with Tmab). Patients received weekly paclitaxel plus Tmab as the second-line chemotherapy. The primary endpoint was the overall response rate (ORR; threshold ORR=20% and expected ORR=35%).Twenty-eight patients were enrolled. ORR was 21.4%. The median progression-free survival (PFS) was 4.6 months. The median overall survival (OS) was 9.6 months. No significant differences were observed in ORR, PFS, or OS between the Tmab beyond progression (TBP) group (n=20) and the non-TBP group (n=8). However, in the TBP group, a therapeutic effect was associated with the duration of PFS in the first-line Tmab treatment [≥6 months PFS in the first-line Tmab treatment (n=10) vs.6 months (n=10); ORR: 40 and 10%, P=0.303, PFS: 6.2 and 2.8 months, P=0.005, OS: 15.8 and 6.5 months, P=0.006, respectively].Weekly paclitaxel plus Tmab was not superior as second-line chemotherapy for HER2-positive gastric cancer patients, but may be effective for patients who showed better responses to Tmab-combined chemotherapy in the first-line treatment.

Published
2019
Full Text
View/download PDF

14. Heterologous functional expression of ascidian Nav1 channels and close relationship with the evolutionary ancestor of vertebrate Nav channels

Author

Daijiro Chiba, Yuka Jinno, Måns Aspåker, Natsuki Eguchi, Masaki Hashimoto, Risa Mori-Kreiner, Atsuo Nishino, Takafumi Kawai, Junko M. Nishino, Akira Kawanabe, Yukio Ohtsuka, and Yasushi Okamura

Subjects
0301 basic medicine, ascidian, Xenopus, Gene Expression, Gating, Voltage-Gated Sodium Channels, Biochemistry, Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, axon initial segment, anti-MAP2, anti–microtubule-associated protein 2, voltage clamp, Phylogeny, CiNav1a, ascidian Ciona Nav1, cRNA, complementary RNA, Editors' Pick, Cell biology, Ciona intestinalis, AP, alkaline phosphatase, hβ1, human β1 subunit, PBST, PBS containing 0.1% Tween-20, Squid giant axon, Research Article, sodium channel, DDBJ, DNA Data Bank of Japan, I–V, current–voltage, Biology, hNav1.5, human Nav1.5, 03 medical and health sciences, cDNA, complementary DNA, ankyrin, chordate, ABM, ankyrin-binding motif, PDB, Protein Data Bank, evolution, TEVC, two-electrode voltage clamp, Animals, inactivation, TTX, tetrodotoxin, Molecular Biology, Ion channel, AIS, axon initial segment, cut-open oocyte, 030102 biochemistry & molecular biology, Nav, voltage-gated sodium channel, Sodium channel, Sodium, Cell Biology, HEK293T, human embryonic kidney 293T, biology.organism_classification, Axon initial segment, Ciona, 030104 developmental biology, ion channel, Heterologous expression, rNav1.4, rat Nav1.4, Urochordata, DIG, digoxigenin, SSC, saline sodium citrate
Abstract

Voltage-gated sodium channels (Nav1s) are responsible for the initiation and propagation of action potentials in neurons, muscle, and endocrine cells. Many clinically used drugs such as local anesthetics and antiarrhythmics inhibit Nav1s, and a variety of inherited human disorders are caused by mutations in Nav1 genes. Nav1s consist of the main α subunit and several auxiliary β subunits. Detailed information on the structure-function relationships of Nav1 subunits has been obtained through heterologous expression experiments and analyses of protein structures. The basic properties of Nav1s, including their gating and ion permeation, were classically described in the squid giant axon and other invertebrates. However, heterologous functional expression of Nav1s from marine invertebrates has been unsuccessful. Ascidians belong to the Urochordata, a sister group of vertebrates, and the larval central nervous system of ascidians shows a similar plan to that of vertebrates. Here, we report the biophysical properties of ascidian Ciona Nav1 (CiNav1a) heterologously expressed in Xenopus oocytes. CiNav1a exhibited tetrodotoxin-insensitive sodium currents with rapid gating kinetics of activation and inactivation. Furthermore, consistent with the fact that the Ciona genome lacks orthologous genes to vertebrate β subunits, the human β1 subunit did not influence the gating properties when coexpressed with CiNav1a. Interestingly, CiNav1a contains an ankyrin-binding motif in the II-III linker, which can be targeted to the axon initial segment of mammalian cortical neurons. Our findings provide a platform to gain insight into the evolutionary and biophysical properties of Nav1s, which are important for the development of targeted therapeutics.

Published
2021

15. 980P Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors

Author

T. Semba, Toshio Shimizu, Y. Nakamura, Tsuyoshi Koyama, S. Shiono, H. Ida, Shu Yazaki, Kan Yonemori, K. Yamaguchi, Shunsuke Kondo, Satoru Iwasa, Takao Takase, Y. Katsuya, Takuya Suzuki, S. Takashima, K. Shitara, Kazuki Sudo, Noboru Yamamoto, M. Nishino, and Jun Sato

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, chemistry.chemical_compound, chemistry, Internal medicine, Phase (matter), medicine, In patient, Nivolumab, business, Eribulin
Published
2021
Full Text
View/download PDF

16. Ultraviolet B radiation from a compact fluorescent lamp for tomato disease control

Author

M. Arii, K. Watanabe, K. Uchihashi, F. Sato, T. Kanto, and M. Nishino

Subjects
biology, Horticulture, Plant disease resistance, biology.organism_classification, law.invention, Conidium, law, Germination, Spore germination, Compact fluorescent lamp, Fluorescent lamp, Powdery mildew, Botrytis cinerea
Abstract

We previously produced an ultraviolet B (UV-B) lighting system to control strawberry powdery mildew. Since then, Panasonic Corp. has produced a new compact fluorescent lamp that can provide continuous illumination longer than a previous version of the lamp, and at a lower price. We have begun applying this new compact lamp to control tomato diseases. For this study, tomato was grown in the winter over two growing seasons using a nutrient flow technique (NFT) system in a 300-m2 greenhouse. The compact UV-B fluorescent lamp was suspended from the ceiling, approximately 1-2 m above the tomato plants. Tomato plants were irradiated using compact UV-B fluorescent lamps daily during 23:00-23:30 and 0:00-0:30 from Oct 2014 to Mar 2015, and during 23:00-2:00 from Oct 2015 to Feb 2016. Plants received light energy of 0.1-1.5 kJ m-2 d-1 in 2014 and 0.2-1.4 kJ m-2 d-1 in 2015. Diseased leaves or fruits that had been infected with powdery mildew (Oidium neolycopersici) or gray mold (Botrytis cinerea) were hung at approximately 2 m height as inocula 1-2 months after starting irradiation. Both diseases were suppressed effectively. The best control values against powdery mildew were 92.0% the first year and 91.2% the second year. The control value against gray mold was 65.6% in the first year. The UV-B radiation applied did not suppress germination of tomato powdery mildew conidia in laboratory tests. Furthermore, crude extracts from radiated tomato leaves exhibited antifungal activity. From these findings, we conclude that the compact UV-B fluorescent lamp can induce tomato plant resistance against fungal pathogens. Future studies are expected to produce a new radiation system to control tomato diseases.

Published
2018
Full Text
View/download PDF

17. ES17.03 Imaging of Pneumonitis

Author

M. Nishino

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, ARDS, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Radiation therapy, Pneumonia, Internal medicine, medicine, Lung cancer, business, Idiopathic interstitial pneumonia, Hypersensitivity pneumonitis, Pneumonitis
Abstract

Pneumonitis is one of the major adverse events from systemic anti-cancer therapy and provides clinical challenges in oncology practice. Imaging plays a key role in detection, diagnosis, and monitoring of pneumonitis in cancer patients. This lecture will discuss 1) diagnosis and monitoring of pneumonitis using CT patterns on imaging, 2) spectrum of CT patterns of pneumonitis focusing on immune-checkpoint inhibitors (ICI) and epidermal growth factor receptor (EGFR) inhibitors, and 3) emerging challenges and pitfalls in the era of COVID-19 pandemic. When approaching pneumonitis on imaging, it is very important to note that pneumonitis represents lung’s response to injury. The lung’s response patterns to injury has several histologic manifestations with corresponding CT patterns, which are originally described in idiopathic interstitial pneumonias and are also noted in the setting of pneumonitis secondary to cancer therapy. The assessment of extent and distribution of the lung abnormalities on CT is very important to recognize the distinct CT patterns. The spectrum of CT patterns is noted in pneumonitis from cancer therapies, and are associated with clinical severity of pneumonitis. Recognition of CT patterns helps to diagnosis, monitor, and prognosticate pneumonitis in cancer patients. In terms of pneumonitis from individual agents, the lecture will focus on pneumonitis from ICI and EGFR inhibitors, which are two representative agents used in lung cancer that can cause pneumonitis. ICI pneumonitis is relatively rare, but clinically serious and potentially life-threatening toxicity from ICI therapy, and is a leading cause of anti-PD-1/PD-L1-related deaths. The incidence of ICI pneumonitis is higher in lung cancer than in other cancers, indicating that pneumonitis is a particularly important issue in patients with lung cancer. The representative CT patterns of ICI pneumonitis include AIP/ARDS pattern, COP pattern, NSIP pattern, and HP pattern. Among these patterns, COP pattern is most common, noted in about two thirds of the patients. AIP/ARDS patten has the most severe clinical presentation and requires immediate clinical attention. The details of each of these CT patterns will be described with case presentations to demonstrate the characteristic features with clinical correlation. Pneumonitis is also a recognized class-effect for EGFR inhibitors. A higher incidence rate in Japanese population is noted, with a high mortality rate in the cohort studies from Japan, which is confirmed by the recent meta-analysis of 153 EGFR inhibitor trials in non-small cell lung cancer. The spectrum of CT patterns is also noted in EGFR inhibitor pneumonitis, and correlates with clinical severity and outcome. As the emerging issues with the advances of cancer therapies and the recent COVID pandemic, pneumonitis from combination ICI and radiotherapy is discussed, featuring the imaging manifestations from both ICI pneumonitis and radiation pneumonitis. Finally, the overlapping imaging features of ICI pneumonitis and COVID-19 pneumonia are presented, to demonstrate a unique challenge in the era of COVID-19 pandemic. The lecture concludes emphasizing the importance of multidisciplinary approach to further understand these emerging challenges to optimize diagnosis and management of pneumonitis in cancer patients. Abbreviations: AIP = Acute Interstitial Pneumonia;ARDS = Acute Respiratory Distress Syndrome;COP = Cryptogenic Organizing Pneumonia;HP = Hypersensitivity Pneumonitis;NSIP = Non-Specific Interstitial Pneumonia References: Nishino M, Sholl LM, Hatabu H, Ramaiya NH, Hodi FS. Anti-PD-1 Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015 Jul 16;373(3):288-290. Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH. Drug-related pneumonitis during mTOR inhibitor therapy in patients with neuroendocrine tumors: A radiographic pattern-based approach. Eur J Cancer. 2016 Jan;53:163-70. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 inhibitor-related pneu onitis in advanced cancer patients: Radiographic patterns and clinical course. Clin Cancer Res. 201622:6051-6060. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of PD-1 inhibitor-related pneumonitis in advanced cancer patients: A systematic review and meta-analysis. JAMA Oncol. 2016;2:1607-1616. Suh CH, Park HS, Kim KW, Pyo J, Hatabu H, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer. 2018;123:60-69. Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2019;200:e31-e43. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology. 2021;298(3):550-566. Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655-668. Nishino M, Hatabu H, Hodi FS. Imaging of Cancer Immunotherapy: Current approaches and future directions. Radiology. 2019;290:9-22. Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Imaging of precision therapy for lung cancer: Current State-of-the-Art. Radiology. 2019;293:15-29. PMID: 31385753 PMC6776234 Keywords: pneumonitis, computed tomography, Immune-checkpoint inhibitor

Published
2021
Full Text
View/download PDF

19. P2689Irregular protrusion area is associated with incidence of cardiac events after implantation of new generation drug-eluting stents - optical coherence tomography study

Author

K Yanagawa, M Nishino, H Nakamura, Y Matsuhiro, K Yasumoto, A Tanaka, Y Matsunaga, D Nakamura, M Yano, M Yamato, Y Egami, R Shutta, and J Tanouchi

Subjects
Drug, medicine.medical_specialty, Optical coherence tomography, medicine.diagnostic_test, business.industry, media_common.quotation_subject, Incidence (epidemiology), medicine, Radiology, Cardiology and Cardiovascular Medicine, business, media_common
Abstract

Background Several studies using optical coherence tomography (OCT) have shown that the prevalence of irregular protrusion was associated with the incidence of adverse cardiac events. However, the correlation between cardiac events and protrusion area is not well investigated. Method One hundred twenty-nine consecutive patients with 138 clesions with 2nd and 3rd generation drug-eluting stents (DES) which had pre-stenting and post-stenting OCT imaging between April 2016 and April 2018 were evaluated. We compared baseline characteristics, procedure findings and OCT findings including minimum stent area, protrusion type and maximum protrusion area between target lesion revascularization (TLR) group and non-TLR group. Results TLR occurred in 12 (9.3%) in 129 patients. The baseline characteristics and procedure findings were similar between TLR group and non-TLR group. Univariate analysis revealed that maximum irregular protrusion area was significantly larger (0.51 [0.00–0.63] vs 0.00 [0.00–0.27], p=0.036) in TLR group than non-TLR group. Receiver operating characteristic curve analysis revealed that the suitable cutoff value of maximum irregular protrusion area were 0.43mm2 for TLR. In multivariate analysis using the parameters with p value Odd's ratio (95% CI) P value Major irregular protrusion (≥0.43mm2) 17.3 (3.63–82.6) Conclusion Major irregular protrusion (>0.43mm2) in post-stenting OCT findings may be a powerful predictor of TLR in the patients with new generation DES.

Published
2019
Full Text
View/download PDF

20. An α7-related nicotinic acetylcholine receptor mediates the ciliary arrest response in pharyngeal gill slits of

Author

Junko M. Nishino, Kei Jokura, Atsuo Nishino, and Michio Ogasawara

Subjects
0301 basic medicine, Gills, alpha7 Nicotinic Acetylcholine Receptor, Physiology, Xenopus, Aquatic Science, Receptors, Nicotinic, 03 medical and health sciences, 0302 clinical medicine, medicine, Animals, Receptor, Molecular Biology, Ecology, Evolution, Behavior and Systematics, Acetylcholine receptor, biology, biology.organism_classification, Cell biology, Ciona intestinalis, Ciona, Nicotinic acetylcholine receptor, 030104 developmental biology, Nicotinic agonist, Insect Science, Cholinergic, Animal Science and Zoology, 030217 neurology & neurosurgery, Acetylcholine, medicine.drug
Abstract

Ciliary movement is a fundamental process to support animal life, and the movement pattern may be altered in response to external stimuli under the control of nervous systems. Juvenile and adult ascidians have ciliary arrays around their pharyngeal gill slits (stigmata), and continuous beating is interrupted for seconds by mechanical stimuli on other parts of the body. Although it has been suggested that neural transmission to evoke ciliary arrest is cholinergic, its molecular basis has not yet been elucidated in detail. We herein attempted to clarify the molecular mechanisms underlying this neurociliary transmission in the model ascidian Ciona. Acetylcholinesterase histochemical staining showed strong signals on the laterodistal ciliated cells of stigmata, hereafter referred to as trapezial cells. The direct administration of acetylcholine (ACh) and other agonists of nicotinic ACh receptors (nAChRs) onto ciliated cells reliably evoked ciliary arrest that persisted for seconds in a dose-dependent manner. Only one isoform among all nAChR subunits encoded in the Ciona genome, called nAChR-A7/8-1, a relative of vertebrate α7 nAChRs, was expressed by trapezial cells. Exogenously expressed nAChR-A7/8-1 on Xenopus oocytes responded to ACh and other agonists with consistent pharmacological traits to those observed in vivo. Further efforts to examine signaling downstream of this receptor revealed that an inhibitor of phospholipase C (PLC) hampered ACh-induced ciliary arrest. We herein propose that homomeric α7-related nAChR-A7/8-1 mediates neurociliary transmission in Ciona stigmata to elicit persistent ciliary arrest by recruiting intracellular Ca2+ signaling.

Published
2019

22. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status

Author

B. Ricciuti, K. Arbour, J. Lin, A. Vajdi, M. Tolstorukov, L. Hong, J. Zhang, N. Vokes, Y. Li, L. Spurr, A. Cherniack, G. Recondo, G. Lamberti, H. Rizvi, J. Egger, A. Plodkowski, S. Khosrowjerdi, S. Digumarthy, N. Vaz, H. Park, M. Nishino, L. Sholl, D. Barbie, M. Altan, J. Heymach, F. Skoulidis, J. Gainor, M. Hellmann, and M. Awad

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2021
Full Text
View/download PDF

23. 534MO First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours

Author

M. Kondo, T. Ozaki, Kan Yonemori, Teruhiko Yoshida, Satoru Iwasa, Tsuyoshi Koyama, Kazuo Tamura, Toshio Shimizu, M. Nishino, Shunsuke Kondo, Kazuki Sudo, and Noboru Yamamoto

Subjects
Oncology, business.industry, Immune checkpoint inhibitors, Prostaglandin E2 receptor, Antagonist, Cancer research, Medicine, In patient, Hematology, First in human, Nivolumab, business
Published
2020
Full Text
View/download PDF

24. Efficacy of the H2-receptor antagonist famotidine on chronic spontaneous urticaria in children

Author

Mutsuzo Takada, M Nishino, Yoshihiko Sakurai, and Hideo Takatsuka

Subjects
medicine.medical_specialty, Acute urticaria, business.industry, Medical record, Antagonist, Famotidine, chemistry.chemical_compound, Symptom relief, Histamine H2 receptor, chemistry, Anesthesia, Internal medicine, medicine, Outpatient clinic, business, Histamine, medicine.drug
Abstract

Urticaria is a common pediatric skin disorder. Histamine H1-receptor antagonists are effective in chronic as well as acute urticaria. When H1-anti-histamines are ineffective, add-on use of H2-receptor antagonists is thought to give better symptom relief. However, there are few reports on the therapeutic efficacy in pediatric patients. We retrospectively reviewed the medical records of pediatric patients with chronic spontaneous urticaria (csU) who met the following criteria. They were consulted our outpatient clinic between April 2010 and March 2012; were unsuccessfully treated with H1 antihistamines; and were treated with add-on H2-receptor antagonist (famotidine). In six patients who met the inclusion criteria (mean age 6.1 ± 5.1 years), urticaria activity score was significantly decreased from 4.3 ± 0.8 just before administration of famotidine to 1.3 ± 1.0 on the first outpatient visit within 4 weeks after the first administration of famotidine (p

Published
2013
Full Text
View/download PDF

25. A case of Kawasaki disease with second-degree atrioventricular block (Wenckebach type)

Author

Masahiko Matsumura, Chutaro Yamanaka, Shinichiro Yoshimura, Shinji Maeda, Hideo Takatsuka, Yoshihiko Sakurai, M Nishino, Masahiro Fukushima, Takeshi Shiba, Mitsuhiko Nambu, and Naoki Miki

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Kawasaki disease, medicine.disease, business, Second-degree atrioventricular block
Published
2013
Full Text
View/download PDF

26. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Author

Klionsky, D.J. Abdelmohsen, K. Abe, A. Abedin, M.J. Abeliovich, H. Arozena, A.A. Adachi, H. Adams, C.M. Adams, P.D. Adeli, K. Adhihetty, P.J. Adler, S.G. Agam, G. Agarwal, R. Aghi, M.K. Agnello, M. Agostinis, P. Aguilar, P.V. Aguirre-Ghiso, J. Airoldi, E.M. Ait-Si-Ali, S. Akematsu, T. Akporiaye, E.T. Al-Rubeai, M. Albaiceta, G.M. Albanese, C. Albani, D. Albert, M.L. Aldudo, J. Algül, H. Alirezaei, M. Alloza, I. Almasan, A. Almonte-Beceril, M. Alnemri, E.S. Alonso, C. Altan-Bonnet, N. Altieri, D.C. Alvarez, S. Alvarez-Erviti, L. Alves, S. Amadoro, G. Amano, A. Amantini, C. Ambrosio, S. Amelio, I. Amer, A.O. Amessou, M. Amon, A. An, Z. Anania, F.A. Andersen, S.U. Andley, U.P. Andreadi, C.K. Andrieu-Abadie, N. Anel, A. Ann, D.K. Anoopkumar-Dukie, S. Antonioli, M. Aoki, H. Apostolova, N. Aquila, S. Aquilano, K. Araki, K. Arama, E. Aranda, A. Araya, J. Arcaro, A. Arias, E. Arimoto, H. Ariosa, A.R. Armstrong, J.L. Arnould, T. Arsov, I. Asanuma, K. Askanas, V. Asselin, E. Atarashi, R. Atherton, S.S. Atkin, J.D. Attardi, L.D. Auberger, P. Auburger, G. Aurelian, L. Autelli, R. Avagliano, L. Avantaggiati, M.L. Avrahami, L. Azad, N. Awale, S. Bachetti, T. Backer, J.M. Bae, D.-H. Bae, J.-S. Bae, O.-N. Bae, S.H. Baehrecke, E.H. Baek, S.-H. Baghdiguian, S. Bagniewska-Zadworna, A. Bai, H. Bai, J. Bai, X.-Y. Bailly, Y. Balaji, K.N. Balduini, W. Ballabio, A. Balzan, R. Banerjee, R. Bánhegyi, G. Bao, H. Barbeau, B. Barrachina, M.D. Barreiro, E. Bartel, B. Bartolomé, A. Bassham, D.C. Bassi, M.T. Bast, R.C., Jr. Basu, A. Batista, M.T. Batoko, H. Battino, M. Bauckman, K. Baumgarner, B.L. Bayer, K.U. Beale, R. Beaulieu, J.-F. Beck, G.R., Jr. Becker, C. Beckham, J.D. Bédard, P.-A. Bednarski, P.J. Begley, T.J. Behl, C. Behrends, C. Behrens, G.M.N. Behrns, K.E. Bejarano, E. Belaid, A. Belleudi, F. Bénard, G. Berchem, G. Bergamaschi, D. Bergami, M. Berkhout, B. Berliocchi, L. Bernard, A. Bernard, M. Bernassola, F. Bertolotti, A. Bess, A.S. Besteiro, S. Bettuzzi, S. Bhalla, S. Bhattacharyya, S. Bhutia, S.K. Biagosch, C. Bianchi, M.W. Biard-Piechaczyk, M. Billes, V. Bincoletto, C. Bingol, B. Bird, S.W. Bitoun, M. Bjedov, I. Blackstone, C. Blanc, L. Blanco, G.A. Blomhoff, H.K. Boada-Romero, E. Böckler, S. Boes, M. Boesze-Battaglia, K. Boise, L.H. Bolino, A. Boman, A. Bonaldo, P. Bordi, M. Bosch, J. Botana, L.M. Botti, J. Bou, G. Bouché, M. Bouchecareilh, M. Boucher, M.-J. Boulton, M.E. Bouret, S.G. Boya, P. Boyer-Guittaut, M. Bozhkov, P.V. Brady, N. Braga, V.M.M. Brancolini, C. Braus, G.H. Bravo-San-Pedro, J.M. Brennan, L.A. Bresnick, E.H. Brest, P. Bridges, D. Bringer, M.-A. Brini, M. Brito, G.C. Brodin, B. Brookes, P.S. Brown, E.J. Brown, K. Broxmeyer, H.E. Bruhat, A. Brum, P.C. Brumell, J.H. Brunetti-Pierri, N. Bryson-Richardson, R.J. Buch, S. Buchan, A.M. Budak, H. Bulavin, D.V. Bultman, S.J. Bultynck, G. Bumbasirevic, V. Burelle, Y. Burke, R.E. Burmeister, M. Bütikofer, P. Caberlotto, L. Cadwell, K. Cahova, M. Cai, D. Cai, J. Cai, Q. Calatayud, S. Camougrand, N. Campanella, M. Campbell, G.R. Campbell, M. Campello, S. Candau, R. Caniggia, I. Cantoni, L. Cao, L. Caplan, A.B. Caraglia, M. Cardinali, C. Cardoso, S.M. Carew, J.S. Carleton, L.A. Carlin, C.R. Carloni, S. Carlsson, S.R. Carmona-Gutierrez, D. Carneiro, L.A.M. Carnevali, O. Carra, S. Carrier, A. Carroll, B. Casas, C. Casas, J. Cassinelli, G. Castets, P. Castro-Obregon, S. Cavallini, G. Ceccherini, I. Cecconi, F. Cederbaum, A.I. Ceña, V. Cenci, S. Cerella, C. Cervia, D. Cetrullo, S. Chaachouay, H. Chae, H.-J. Chagin, A.S. Chai, C.-Y. Chakrabarti, G. Chamilos, G. Chan, E.Y.W. Chan, M.T.V. Chandra, D. Chandra, P. Chang, C.-P. Chang, R.C.-C. Chang, T.Y. Chatham, J.C. Chatterjee, S. Chauhan, S. Che, Y. Cheetham, M.E. Cheluvappa, R. Chen, C.-J. Chen, G. Chen, G.-C. Chen, G. Chen, H. Chen, J.W. Chen, J.-K. Chen, M. Chen, M. Chen, P. Chen, Q. Chen, Q. Chen, S.-D. Chen, S. Chen, S.S.-L. Chen, W. Chen, W.-J. Chen, W.Q. Chen, W. Chen, X. Chen, Y.-H. Chen, Y.-G. Chen, Y. Chen, Y. Chen, Y. Chen, Y.-J. Chen, Y.-Q. Chen, Y. Chen, Z. Chen, Z. Cheng, A. Cheng, C.H.K. Cheng, H. Cheong, H. Cherry, S. Chesney, J. Cheung, C.H.A. Chevet, E. Chi, H.C. Chi, S.-G. Chiacchiera, F. Chiang, H.-L. Chiarelli, R. Chiariello, M. Chieppa, M. Chin, L.-S. Chiong, M. Chiu, G.N.C. Cho, D.-H. Cho, S.-G. Cho, W.C. Cho, Y.-Y. Cho, Y.-S. Choi, A.M.K. Choi, E.-J. Choi, E.-K. Choi, J. Choi, M.E. Choi, S.-I. Chou, T.-F. Chouaib, S. Choubey, D. Choubey, V. Chow, K.-C. Chowdhury, K. Chu, C.T. Chuang, T.-H. Chun, T. Chung, H. Chung, T. Chung, Y.-L. Chwae, Y.-J. Cianfanelli, V. Ciarcia, R. Ciechomska, I.A. Ciriolo, M.R. Cirone, M. Claerhout, S. Clague, M.J. Cl� ria, J. Clarke, P.G.H. Clarke, R. Clementi, E. Cleyrat, C. Cnop, M. Coccia, E.M. Cocco, T. Codogno, P. Coers, J. Cohen, E.E.W. Colecchia, D. Coletto, L. Coll, N.S. Colucci-Guyon, E. Comincini, S. Condello, M. Cook, K.L. Coombs, G.H. Cooper, C.D. Cooper, J.M. Coppens, I. Corasaniti, M.T. Corazzari, M. Corbalan, R. Corcelle-Termeau, E. Cordero, M.D. Corral-Ramos, C. Corti, O. Cossarizza, A. Costelli, P. Costes, S. Cotman, S.L. Coto-Montes, A. Cottet, S. Couve, E. Covey, L.R. Cowart, L.A. Cox, J.S. Coxon, F.P. Coyne, C.B. Cragg, M.S. Craven, R.J. Crepaldi, T. Crespo, J.L. Criollo, A. Crippa, V. Cruz, M.T. Cuervo, A.M. Cuezva, J.M. Cui, T. Cutillas, P.R. Czaja, M.J. Czyzyk-Krzeska, M.F. Dagda, R.K. Dahmen, U. Dai, C. Dai, W. Dai, Y. Dalby, K.N. Valle, L.D. Dalmasso, G. D'amelio, M. Damme, M. Darfeuille-Michaud, A. Dargemont, C. Darley-Usmar, V.M. Dasarathy, S. Dasgupta, B. Dash, S. Dass, C.R. Davey, H.M. Davids, L.M. Dávila, D. Davis, R.J. Dawson, T.M. Dawson, V.L. Daza, P. de Belleroche, J. de Figueiredo, P. de Figueiredo, R.C.B.Q. de la Fuente, J. De Martino, L. De Matteis, A. De Meyer, G.R.Y. De Milito, A. De Santi, M. de Souza, W. De Tata, V. De Zio, D. Debnath, J. Dechant, R. Decuypere, J.-P. Deegan, S. Dehay, B. Del Bello, B. Del Re, D.P. Delage-Mourroux, R. Delbridge, L.M.D. Deldicque, L. Delorme-Axford, E. Deng, Y. Dengjel, J. Denizot, M. Dent, P. Der, C.J. Deretic, V. Derrien, B. Deutsch, E. Devarenne, T.P. Devenish, R.J. Di Bartolomeo, S. Di Daniele, N. Di Domenico, F. Di Nardo, A. Di Paola, S. Di Pietro, A. Di Renzo, L. Di Antonio, A. Díaz-Araya, G. Díaz-Laviada, I. Diaz-Meco, M.T. Diaz-Nido, J. Dickey, C.A. Dickson, R.C. Diederich, M. Digard, P. Dikic, I. Dinesh-Kumar, S.P. Ding, C. Ding, W.-X. Ding, Z. Dini, L. Distler, J.H.W. Diwan, A. Djavaheri-Mergny, M. Dmytruk, K. Dobson, R.C.J. Doetsch, V. Dokladny, K. Dokudovskaya, S. Donadelli, M. Dong, X.C. Dong, X. Dong, Z. Donohue, T.M., Jr. Donohue-Jr, T.M. Doran, K.S. D'orazi, G. Dorn, G.W., II Dosenko, V. Dridi, S. Drucker, L. Du, J. Du, L.-L. Du, L. du Toit, A. Dua, P. Duan, L. Duann, P. Dubey, V.K. Duchen, M.R. Duchosal, M.A. Duez, H. Dugail, I. Dumit, V.I. Duncan, M.C. Dunlop, E.A. Dunn, W.A., Jr. Dupont, N. Dupuis, L. Durán, R.V. Durcan, T.M. Duvezin-Caubet, S. Duvvuri, U. Eapen, V. Ebrahimi-Fakhari, D. Echard, A. Eckhart, L. Edelstein, C.L. Edinger, A.L. Eichinger, L. Eisenberg, T. Eisenberg-Lerner, A. Eissa, N.T. El-Deiry, W.S. El-Khoury, V. Elazar, Z. Eldar-Finkelman, H. Elliott, C.J.H. Emanuele, E. Emmenegger, U. Engedal, N. Engelbrecht, A.-M. Engelender, S. Enserink, J.M. Erdmann, R. Erenpreisa, J. Eri, R. Eriksen, J.L. Erman, A. Escalante, R. Eskelinen, E.-L. Espert, L. Esteban-Martínez, L. Evans, T.J. Fabri, M. Fabrias, G. Fabrizi, C. Facchiano, A. Færgeman, N.J. Faggioni, A. Fairlie, W.D. Fan, C. Fan, D. Fan, J. Fang, S. Fanto, M. Fanzani, A. Farkas, T. Faure, M. Favier, F.B. Fearnhead, H. Federici, M. Fei, E. Felizardo, T.C. Feng, H. Feng, Y. Feng, Y. Ferguson, T.A. Fernández, Á.F. Fernandez-Barrena, M.G. Fernandez-Checa, J.C. Fernández-López, A. Fernandez-Zapico, M.E. Feron, O. Ferraro, E. Ferreira-Halder, C.V. Fesus, L. Feuer, R. Fiesel, F.C. Filippi-Chiela, E.C. Filomeni, G. Fimia, G.M. Fingert, J.H. Finkbeiner, S. Finkel, T. Fiorito, F. Fisher, P.B. Flajolet, M. Flamigni, F. Florey, O. Florio, S. Floto, R.A. Folini, M. Follo, C. Fon, E.A. Fornai, F. Fortunato, F. Fraldi, A. Franco, R. Francois, A. François, A. Frankel, L.B. Fraser, I.D.C. Frey, N. Freyssenet, D.G. Frezza, C. Friedman, S.L. Frigo, D.E. Fu, D. Fuentes, J.M. Fueyo, J. Fujitani, Y. Fujiwara, Y. Fujiya, M. Fukuda, M. Fulda, S. Fusco, C. Gabryel, B. Gaestel, M. Gailly, P. Gajewska, M. Galadari, S. Galili, G. Galindo, I. Galindo, M.F. Galliciotti, G. Galluzzi, L. Galluzzi, L. Galy, V. Gammoh, N. Gandy, S. Ganesan, A.K. Ganesan, S. Ganley, I.G. Gannagé, M. Gao, F.-B. Gao, F. Gao, J.-X. Nannig, L.G. Véscovi, E.G. Garcia-Macía, M. Garcia-Ruiz, C. Garg, A.D. Garg, P.K. Gargini, R. Gassen, N.C. Gatica, D. Gatti, E. Gavard, J. Gavathiotis, E. Ge, L. Ge, P. Ge, S. Gean, P.-W. Gelmetti, V. Genazzani, A.A. Geng, J. Genschik, P. Gerner, L. Gestwicki, J.E. Gewirtz, D.A. Ghavami, S. Ghigo, E. Ghosh, D. Giammarioli, A.M. Giampieri, F. Giampietri, C. Giatromanolaki, A. Gibbings, D.J. Gibellini, L. Gibson, S.B. Ginet, V. Giordano, A. Giorgini, F. Giovannetti, E. Girardin, S.E. Gispert, S. Giuliano, S. Gladson, C.L. Glavic, A. Gleave, M. Godefroy, N. Gogal, R.M., Jr. Gokulan, K. Goldman, G.H. Goletti, D. Goligorsky, M.S. Gomes, A.V. Gomes, L.C. Gomez, H. Gomez-Manzano, C. Gómez-Sánchez, R. Gonçalves, D.A.P. Goncu, E. Gong, Q. Gongora, C. Gonzalez, C.B. Gonzalez-Alegre, P. Gonzalez-Cabo, P. González-Polo, R.A. Goping, I.S. Gorbea, C. Gorbunov, N.V. Goring, D.R. Gorman, A.M. Gorski, S.M. Goruppi, S. Goto-Yamada, S. Gotor, C. Gottlieb, R.A. Gozes, I. Gozuacik, D. Graba, Y. Graef, M. Granato, G.E. Grant, G.D. Grant, S. Gravina, G.L. Green, D.R. Greenhough, A. Greenwood, M.T. Grimaldi, B. Gros, F. Grose, C. Groulx, J.-F. Gruber, F. Grumati, P. Grune, T. Guan, J.-L. Guan, K.-L. Guerra, B. Guillen, C. Gulshan, K. Gunst, J. Guo, C. Guo, L. Guo, M. Guo, W. Guo, X.-G. Gust, A.A. Gustafsson, Å.B. Gutierrez, E. Gutierrez, M.G. Gwak, H.-S. Haas, A. Haber, J.E. Hadano, S. Hagedorn, M. Hahn, D.R. Halayko, A.J. Hamacher-Brady, A. Hamada, K. Hamai, A. Hamann, A. Hamasaki, M. Hamer, I. Hamid, Q. Hammond, E.M. Han, F. Han, W. Handa, J.T. Hanover, J.A. Hansen, M. Harada, M. Harhaji-Trajkovic, L. Harper, J.W. Harrath, A.H. Harris, A.L. Harris, J. Hasler, U. Hasselblatt, P. Hasui, K. Hawley, R.G. Hawley, T.S. He, C. He, C.Y. He, F. He, G. He, R.-R. He, X.-H. He, Y.-W. He, Y.-Y. Heath, J.K. Hébert, M.-J. Heinzen, R.A. Helgason, G.V. Hensel, M. Henske, E.P. Her, C. Herman, P.K. Hernández, A. Hernandez, C. Hernández-Tiedra, S. Hetz, C. Hiesinger, P.R. Higaki, K. Hilfiker, S. Hill, B.G. Hill, J.A. Hill, W.D. Hino, K. Hofius, D. Hofman, P. Höglinger, G.U. Höhfeld, J. Holz, M.K. Hong, Y. Hood, D.A. Hoozemans, J.J.M. Hoppe, T. Hsu, C. Hsu, C.-Y. Hsu, L.-C. Hu, D. Hu, G. Hu, H.-M. Hu, H. Hu, M.C. Hu, Y.-C. Hu, Z.-W. Hua, F. Hua, Y. Huang, C. Huang, H.-L. Huang, K.-H. Huang, K.-Y. Huang, S. Huang, S. Huang, W.-P. Huang, Y.-R. Huang, Y. Huang, Y. Huber, T.B. Huebbe, P. Huh, W.-K. Hulmi, J.J. Hur, G.M. Hurley, J.H. Husak, Z. Hussain, S.N.A. Hussain, S. Hwang, J.J. Hwang, S. Hwang, T.I.S. Ichihara, A. Imai, Y. Imbriano, C. Inomata, M. Into, T. Iovane, V. Iovanna, J.L. Iozzo, R.V. Ip, N.Y. Irazoqui, J.E. Iribarren, P. Isaka, Y. Isakovic, A.J. Ischiropoulos, H. Isenberg, J.S. Ishaq, M. Ishida, H. Ishii, I. Ishmael, J.E. Isidoro, C. Isobe, K.-I. Isono, E. Issazadeh-Navikas, S. Itahana, K. Itakura, E. Ivanov, A.I. Iyer, A.K.V. Izquierdo, J.M. Izumi, Y. Izzo, V. Jäättelä, M. Jaber, N. Jackson, D.J. Jackson, W.T. Jacob, T.G. Jacques, T.S. Jagannath, C. Jain, A. Jana, N.R. Jang, B.K. Jani, A. Janji, B. Jannig, P.R. Jansson, P.J. Jean, S. Jendrach, M. Jeon, J.-H. Jessen, N. Jeung, E.-B. Jia, K. Jia, L. Jiang, H. Jiang, H. Jiang, L. Jiang, T. Jiang, X. Jiang, X. Jiang, Y. Jiang, Y. Jiménez, A. Jin, C. Jin, H. Jin, L. Jin, M. Jin, S. Jinwal, U.K. Jo, E.-K. Johansen, T. Johnson, D.E. Johnson, G.V.W. Johnson, J.D. Jonasch, E. Jones, C. Joosten, L.A.B. Jordan, J. Joseph, A.-M. Joseph, B. Joubert, A.M. Ju, D. Ju, J. Juan, H.-F. Juenemann, K. Juhász, G. Jung, H.S. Jung, J.U. Jung, Y.-K. Jungbluth, H. Justice, M.J. Jutten, B. Kaakoush, N.O. Kaarniranta, K. Kaasik, A. Kabuta, T. Kaeffer, B. Kågedal, K. Kahana, A. Kajimura, S. Kakhlon, O. Kalia, M. Kalvakolanu, D.V. Kamada, Y. Kambas, K. Kaminskyy, V.O. Kampinga, H.H. Kandouz, M. Kang, C. Kang, R. Kang, T.-C. Kanki, T. Kanneganti, T.-D. Kanno, H. Kanthasamy, A.G. Kantorow, M. Kaparakis-Liaskos, M. Kapuy, O. Karantza, V. Karim, M.R. Karmakar, P. Kaser, A. Kaushik, S. Kawula, T. Kaynar, A.M. Ke, P.-Y. Ke, Z.-J. Kehrl, J.H. Keller, K.E. Kemper, J.K. Kenworthy, A.K. Kepp, O. Kern, A. Kesari, S. Kessel, D. Ketteler, R. Kettelhut, I.C. Khambu, B. Khan, M.M. Khandelwal, V.K.M. Khare, S. Kiang, J.G. Kiger, A.A. Kihara, A. Kim, A.L. Kim, C.H. Kim, D.R. Kim, D.-H. Kim, E.K. Kim, H.Y. Kim, H.-R. Kim, J.-S. Kim, J.H. Kim, J.C. Kim, J.H. Kim, K.W. Kim, M.D. Kim, M.-M. Kim, P.K. Kim, S.W. Kim, S.-Y. Kim, Y.-S. Kim, Y. Kimchi, A. Kimmelman, A.C. Kimura, T. King, J.S. Kirkegaard, K. Kirkin, V. Kirshenbaum, L.A. Kishi, S. Kitajima, Y. Kitamoto, K. Kitaoka, Y. Kitazato, K. Kley, R.A. Klimecki, W.T. Klinkenberg, M. Klucken, J. Knævelsrud, H. Knecht, E. Knuppertz, L. Ko, J.-L. Kobayashi, S. Koch, J.C. Koechlin-Ramonatxo, C. Koenig, U. Koh, Y.H. Köhler, K. Kohlwein, S.D. Koike, M. Komatsu, M. Kominami, E. Kong, D. Kong, H.J. Konstantakou, E.G. Kopp, B.T. Korcsmaros, T. Korhonen, L. Korolchuk, V.I. Koshkina, N.V. Kou, Y. Koukourakis, M.I. Koumenis, C. Kovács, A.L. Kovács, T. Kovacs, W.J. Koya, D. Kraft, C. Krainc, D. Kramer, H. Kravic-Stevovic, T. Krek, W. Kretz-Remy, C. Krick, R. Krishnamurthy, M. Kriston-Vizi, J. Kroemer, G. Kruer, M.C. Kruger, R. Ktistakis, N.T. Kuchitsu, K. Kuhn, C. Kumar, A.P. Kumar, A. Kumar, A. Kumar, D. Kumar, D. Kumar, R. Kumar, S. Kundu, M. Kung, H.-J. Kuno, A. Kuo, S.-H. Kuret, J. Kurz, T. Kwok, T. Kwon, T.K. Kwon, Y.T. Kyrmizi, I. La Spada, A.R. Lafont, F. Lahm, T. Lakkaraju, A. Lam, T. Lamark, T. Lancel, S. Landowski, T.H. Lane, D.J.R. Lane, J.D. Lanzi, C. Lapaquette, P. Lapierre, L.R. Laporte, J. Laukkarinen, J. Laurie, G.W. Lavandero, S. Lavie, L. Lavoie, M.J. Law, B.Y.K. Law, H.K.-W. Law, K.B. Layfield, R. Lazo, P.A. Le Cam, L. Le Roch, K.G. Le Stunff, H. Leardkamolkarn, V. Lecuit, M. Lee, B.-H. Lee, C.-H. Lee, E.F. Lee, G.M. Lee, H.-J. Lee, H. Lee, J.K. Lee, J. Lee, J.-H. Lee, J.H. Lee, M. Lee, M.-S. Lee, P.J. Lee, S.W. Lee, S.-J. Lee, S.-J. Lee, S.Y. Lee, S.H. Lee, S.S. Lee, S.-J. Lee, S. Lee, Y.-R. Lee, Y.J. Lee, Y.H. Leeuwenburgh, C. Lefort, S. Legouis, R. Lei, J. Lei, Q.-Y. Leib, D.A. Leibowitz, G. Lekli, I. Lemaire, S.D. Lemasters, J.J. Lemberg, M.K. Lemoine, A. Leng, S. Lenz, G. Lenzi, P. Lerman, L.O. Barbato, D.L. Leu, J.I.J. Leung, H.Y. Levine, B. Lewis, P.A. Lezoualch, F. Li, C. Li, F. Li, F.-J. Li, J. Li, K. Li, L. Li, M. Li, Q. Li, R. Li, S. Li, W. Li, X. Li, Y. Lian, J. Liang, C. Liang, Q. Liao, Y. Liberal, J. Liberski, P.P. Lie, P. Lieberman, A.P. Lim, H.J. Lim, K.-L. Lim, K. Lima, R.T. Lin, C.-S. Lin, C.-F. Lin, F. Lin, F. Lin, F.-C. Lin, K. Lin, K.-H. Lin, P.-H. Lin, T. Lin, W.-W. Lin, Y.-S. Lin, Y. Linden, R. Lindholm, D. Lindqvist, L.M. Lingor, P. Linkermann, A. Liotta, L.A. Lipinski, M.M. Lira, V.A. Lisanti, M.P. Liton, P.B. Liu, B. Liu, C. Liu, C.-F. Liu, F. Liu, H.-J. Liu, J. Liu, J.-J. Liu, J.-L. Liu, K. Liu, L. Liu, L. Liu, Q. Liu, R.-Y. Liu, S. Liu, S. Liu, W. Liu, X.-D. Liu, X. Liu, X.-H. Liu, X. Liu, X. Liu, X. Liu, Y. Liu, Y. Liu, Z. Liu, Z. Liuzzi, J.P. Lizard, G. Ljujic, M. Lodhi, I.J. Logue, S.E. Lokeshwar, B.L. Long, Y.C. Lonial, S. Loos, B. López-Otín, C. López-Vicario, C. Lorente, M. Lorenzi, P.L. Lõrincz, P. Los, M. Lotze, M.T. Lovat, P.E. Lu, B. Lu, B. Lu, J. Lu, Q. Lu, S.-M. Lu, S. Lu, Y. Luciano, F. Luckhart, S. Lucocq, J.M. Ludovico, P. Lugea, A. Lukacs, N.W. Lum, J.J. Lund, A.H. Luo, H. Luo, J. Luo, S. Luparello, C. Lyons, T. Ma, J. Ma, Y. Ma, Y. Ma, Z. Machado, J. Machado-Santelli, G.M. Macian, F. MacIntosh, G.C. MacKeigan, J.P. Macleod, K.F. MacMicking, J.D. MacMillan-Crow, L.A. Madeo, F. Madesh, M. Madrigal-Matute, J. Maeda, A. Maeda, T. Maegawa, G. Maellaro, E. Maes, H. Magariños, M. Maiese, K. Maiti, T.K. Maiuri, L. Maiuri, M.C. Maki, C.G. Malli, R. Malorni, W. Maloyan, A. Mami-Chouaib, F. Man, N. Mancias, J.D. Mandelkow, E.-M. Mandell, M.A. Manfredi, A.A. Manié, S.N. Manzoni, C. Mao, K. Mao, Z. Mao, Z.-W. Marambaud, P. Marconi, A.M. Marelja, Z. Marfe, G. Margeta, M. Margittai, E. Mari, M. Mariani, F.V. Marin, C. Marinelli, S. Mariño, G. Markovic, I. Marquez, R. Martelli, A.M. Martens, S. Martin, K.R. Martin, S.J. Martin, S. Martin-Acebes, M.A. Martín-Sanz, P. Martinand-Mari, C. Martinet, W. Martinez, J. Martinez-Lopez, N. Martinez-Outschoorn, U. Martínez-Velázquez, M. Martinez-Vicente, M. Martins, W.K. Mashima, H. Mastrianni, J.A. Matarese, G. Matarrese, P. Mateo, R. Matoba, S. Matsumoto, N. Matsushita, T. Matsuura, A. Matsuzawa, T. Mattson, M.P. Matus, S. Maugeri, N. Mauvezin, C. Mayer, A. Maysinger, D. Mazzolini, G.D. McBrayer, M.K. McCall, K. McCormick, C. McInerney, G.M. McIver, S.C. McKenna, S. McMahon, J.J. McNeish, I.A. Mechta-Grigoriou, F. Medema, J.P. Medina, D.L. Megyeri, K. Mehrpour, M. Mehta, J.L. Mei, Y. Meier, U.-C. Meijer, A.J. Meléndez, A. Melino, G. Melino, S. de Melo, E.J.T. Mena, M.A. Meneghini, M.D. Menendez, J.A. Menezes, R. Meng, L. Meng, L.-H. Meng, S. Menghini, R. Menko, A.S. Menna-Barreto, R.F.S. Menon, M.B. Meraz-Ríos, M.A. Merla, G. Merlini, L. Merlot, A.M. Meryk, A. Meschini, S. Meyer, J.N. Mi, M.-T. Miao, C.-Y. Micale, L. Michaeli, S. Michiels, C. Migliaccio, A.R. Mihailidou, A.S. Mijaljica, D. Mikoshiba, K. Milan, E. Miller-Fleming, L. Mills, G.B. Mills, I.G. Minakaki, G. Minassian, B.A. Ming, X.-F. Minibayeva, F. Minina, E.A. Mintern, J.D. Minucci, S. Miranda-Vizuete, A. Mitchell, C.H. Miyamoto, S. Miyazawa, K. Mizushima, N. Mnich, K. Mograbi, B. Mohseni, S. Moita, L.F. Molinari, M. Molinari, M. Møller, A.B. Mollereau, B. Mollinedo, F. Mongillo, M. Monick, M.M. Montagnaro, S. Montell, C. Moore, D.J. Moore, M.N. Mora-Rodriguez, R. Moreira, P.I. Morel, E. Morelli, M.B. Moreno, S. Morgan, M.J. Moris, A. Moriyasu, Y. Morrison, J.L. Morrison, L.A. Morselli, E. Moscat, J. Moseley, P.L. Mostowy, S. Motori, E. Mottet, D. Mottram, J.C. Moussa, C.E.-H. Mpakou, V.E. Mukhtar, H. Levy, J.M.M. Muller, S. Muñoz-Moreno, R. Muñoz-Pinedo, C. Münz, C. Murphy, M.E. Murray, J.T. Murthy, A. Mysorekar, I.U. Nabi, I.R. Nabissi, M. Nader, G.A. Nagahara, Y. Nagai, Y. Nagata, K. Nagelkerke, A. Nagy, P. Naidu, S.R. Nair, S. Nakano, H. Nakatogawa, H. Nanjundan, M. Napolitano, G. Naqvi, N.I. Nardacci, R. Narendra, D.P. Narita, M. Nascimbeni, A.C. Natarajan, R. Navegantes, L.C. Nawrocki, S.T. Nazarko, T.Y. Nazarko, V.Y. Neill, T. Neri, L.M. Netea, M.G. Netea-Maier, R.T. Neves, B.M. Ney, P.A. Nezis, I.P. Nguyen, H.T.T. Nguyen, H.P. Nicot, A.-S. Nilsen, H. Nilsson, P. Nishimura, M. Nishino, I. Niso-Santano, M. Niu, H. Nixon, R.A. Njar, V.C.O. Noda, T. Noegel, A.A. Nolte, E.M. Norberg, E. Norga, K.K. Noureini, S.K. Notomi, S. Notterpek, L. Nowikovsky, K. Nukina, N. Nürnberger, T. O'donnell, V.B. O'donovan, T. O'dwyer, P.J. Oehme, I. Oeste, C.L. Ogawa, M. Ogretmen, B. Ogura, Y. Oh, Y.J. Ohmuraya, M. Ohshima, T. Ojha, R. Okamoto, K. Okazaki, T. Oliver, F.J. Ollinger, K. Olsson, S. Orban, D.P. Ordonez, P. Orhon, I. Orosz, L. O'rourke, E.J. Orozco, H. Ortega, A.L. Ortona, E. Osellame, L.D. Oshima, J. Oshima, S. Osiewacz, H.D. Otomo, T. Otsu, K. Ou, J.-H.J. Outeiro, T.F. Ouyang, D.-Y. Ouyang, H. Overholtzer, M. Ozbun, M.A. Ozdinler, P.H. Ozpolat, B. Pacelli, C. Paganetti, P. Page, G. Pages, G. Pagnini, U. Pajak, B. Pak, S.C. Pakos-Zebrucka, K. Pakpour, N. Palková, Z. Palladino, F. Pallauf, K. Pallet, N. Palmieri, M. Paludan, S.R. Palumbo, C. Palumbo, S. Pampliega, O. Pan, H. Pan, W. Panaretakis, T. Pandey, A. Pantazopoulou, A. Papackova, Z. Papademetrio, D.L. Papassideri, I. Papini, A. Parajuli, N. Pardo, J. Parekh, V.V. Parenti, G. Park, J.-I. Park, J. Park, O.K. Parker, R. Parlato, R. Parys, J.B. Parzych, K.R. Pasquet, J.-M. Pasquier, B. Pasumarthi, K.B.S. Patterson, C. Pattingre, S. Pattison, S. Pause, A. Pavenstädt, H. Pavone, F. Pedrozo, Z. Peña, F.J. Peñalva, M.A. Pende, M. Peng, J. Penna, F. Penninger, J.M. Pensalfini, A. Pepe, S. Pereira, G.J.S. Pereira, P.C. de la Cruz, V.P. Pérez-Pérez, M.E. Pérez-Rodríguez, D. Pérez-Sala, D. Perier, C. Perl, A. Perlmutter, D.H. Perrotta, I. Pervaiz, S. Pesonen, M. Pessin, J.E. Peters, G.J. Petersen, M. Petrache, I. Petrof, B.J. Petrovski, G. Phang, J.M. Piacentini, M. Pierdominici, M. Pierre, P. Pierrefite-Carle, V. Pietrocola, F. Pimentel-Muiños, F.X. Pinar, M. Pineda, B. Pinkas-Kramarski, R. Pinti, M. Pinton, P. Piperdi, B. Piret, J.M. Platanias, L.C. Platta, H.W. Plowey, E.D. Pöggeler, S. Poirot, M. Polčic, P. Poletti, A. Poon, A.H. Popelka, H. Popova, B. Poprawa, I. Poulose, S.M. Poulton, J. Powers, S.K. Powers, T. Pozuelo-Rubio, M. Prak, K. Prange, R. Prescott, M. Priault, M. Prince, S. Proia, R.L. Proikas-Cezanne, T. Prokisch, H. Promponas, V.J. Przyklenk, K. Puertollano, R. Pugazhenthi, S. Puglielli, L. Pujol, A. Puyal, J. Pyeon, D. Qi, X. Qian, W.-B. Qin, Z.-H. Qiu, Y. Qu, Z. Quadrilatero, J. Quinn, F. Raben, N. Rabinowich, H. Radogna, F. Ragusa, M.J. Rahmani, M. Raina, K. Ramanadham, S. Ramesh, R. Rami, A. Randall-Demllo, S. Randow, F. Rao, H. Rao, V.A. Rasmussen, B.B. Rasse, T.M. Ratovitski, E.A. Rautou, P.-E. Ray, S.K. Razani, B. Reed, B.H. Reggiori, F. Rehm, M. Reichert, A.S. Rein, T. Reiner, D.J. Reits, E. Ren, J. Ren, X. Renna, M. Reusch, J.E.B. Revuelta, J.L. Reyes, L. Rezaie, A.R. Richards, R.I. Richardson, R. Richetta, C. Riehle, M.A. Rihn, B.H. Rikihisa, Y. Riley, B.E. Rimbach, G. Rippo, M.R. Ritis, K. Rizzi, F. Rizzo, E. Roach, P.J. Robbins, J. Roberge, M. Roca, G. Roccheri, M.C. Rocha, S. Rodrigues, C.M.P. Rodríguez, C.I. de Cordoba, S.R. Rodriguez-Muela, N. Roelofs, J. Rogov, V.V. Rohn, T.T. Rohrer, B. Romanelli, D. Romani, L. Romano, P.S. Roncero, M.I.G. Rosa, J.L. Rosello, A. Rosen, K.V. Rosenstiel, P. Rost-Roszkowska, M. Roth, K.A. Roué, G. Rouis, M. Rouschop, K.M. Ruan, D.T. Ruano, D. Rubinsztein, D.C. Rucker, E.B., III Rudich, A. Rudolf, E. Rudolf, R. Ruegg, M.A. Ruiz-Roldan, C. Ruparelia, A.A. Rusmini, P. Russ, D.W. Russo, G.L. Russo, G. Russo, R. Rusten, T.E. Ryabovol, V. Ryan, K.M. Ryter, S.W. Sabatini, D.M. Sacher, M. Sachse, C. Sack, M.N. Sadoshima, J. Saftig, P. Sagi-Eisenberg, R. Sahni, S. Saikumar, P. Saito, T. Saitoh, T. Sakakura, K. Sakoh-Nakatogawa, M. Sakuraba, Y. Salazar-Roa, M. Salomoni, P. Saluja, A.K. Salvaterra, P.M. Salvioli, R. Samali, A. Sanchez, A.M.J. Sánchez-Alcázar, J.A. Sanchez-Prieto, R. Sandri, M. Sanjuan, M.A. Santaguida, S. Santambrogio, L. Santoni, G. Dos Santos, C.N. Saran, S. Sardiello, M. Sargent, G. Sarkar, P. Sarkar, S. Sarrias, M.R. Sarwal, M.M. Sasakawa, C. Sasaki, M. Sass, M. Sato, K. Sato, M. Satriano, J. Savaraj, N. Saveljeva, S. Schaefer, L. Schaible, U.E. Scharl, M. Schatzl, H.M. Schekman, R. Scheper, W. Schiavi, A. Schipper, H.M. Schmeisser, H. Schmidt, J. Schmitz, I. Schneider, B.E. Schneider, E.M. Schneider, J.L. Schon, E.A. Schönenberger, M.J. Schönthal, A.H. Schorderet, D.F. Schröder, B. Schuck, S. Schulze, R.J. Schwarten, M. Schwarz, T.L. Sciarretta, S. Scotto, K. Scovassi, A.I. Screaton, R.A. Screen, M. Seca, H. Sedej, S. Segatori, L. Segev, N. Seglen, P.O. Seguí-Simarro, J.M. Segura-Aguilar, J. Seiliez, I. Seki, E. Sell, C. Semenkovich, C.F. Semenza, G.L. Sen, U. Serra, A.L. Serrano-Puebla, A. Sesaki, H. Setoguchi, T. Settembre, C. Shacka, J.J. Shajahan-Haq, A.N. Shapiro, I.M. Sharma, S. She, H. Shen, C.-K.J. Shen, C.-C. Shen, H.-M. Shen, S. Shen, W. Sheng, R. Sheng, X. Sheng, Z.-H. Shepherd, T.G. Shi, J. Shi, Q. Shi, Q. Shi, Y. Shibutani, S. Shibuya, K. Shidoji, Y. Shieh, J.-J. Shih, C.-M. Shimada, Y. Shimizu, S. Shin, D.W. Shinohara, M.L. Shintani, M. Shintani, T. Shioi, T. Shirabe, K. Shiri-Sverdlov, R. Shirihai, O. Shore, G.C. Shu, C.-W. Shukla, D. Sibirny, A.A. Sica, V. Sigurdson, C.J. Sigurdsson, E.M. Sijwali, P.S. Sikorska, B. Silveira, W.A. Silvente-Poirot, S. Silverman, G.A. Simak, J. Simmet, T. Simon, A.K. Simon, H.-U. Simone, C. Simons, M. Simonsen, A. Singh, R. Singh, S.V. Singh, S.K. Sinha, D. Sinha, S. Sinicrope, F.A. Sirko, A. Sirohi, K. Sishi, B.J.N. Sittler, A. Siu, P.M. Sivridis, E. Skwarska, A. Slack, R. Slaninová, I. Slavov, N. Smaili, S.S. Smalley, K.S.M. Smith, D.R. Soenen, S.J. Soleimanpour, S.A. Solhaug, A. Somasundaram, K. Son, J.H. Sonawane, A. Song, C. Song, F. Song, H.K. Song, J.-X. Song, W. Soo, K.Y. Sood, A.K. Soong, T.W. Soontornniyomkij, V. Sorice, M. Sotgia, F. Soto-Pantoja, D.R. Sotthibundhu, A. Sousa, M.J. Spaink, H.P. Span, P.N. Spang, A. Sparks, J.D. Speck, P.G. Spector, S.A. Spies, C.D. Springer, W. Clair, D.S. Stacchiotti, A. Staels, B. Stang, M.T. Starczynowski, D.T. Starokadomskyy, P. Steegborn, C. Steele, J.W. Stefanis, L. Steffan, J. Stellrecht, C.M. Stenmark, H. Stepkowski, T.M. Stern, S.T. Stevens, C. Stockwell, B.R. Stoka, V. Storchova, Z. Stork, B. Stratoulias, V. Stravopodis, D.J. Strnad, P. Strohecker, A.M. Ström, A.-L. Stromhaug, P. Stulik, J. Su, Y.-X. Su, Z. Subauste, C.S. Subramaniam, S. Sue, C.M. Suh, S.W. Sui, X. Sukseree, S. Sulzer, D. Sun, F.-L. Sun, J. Sun, J. Sun, S.-Y. Sun, Y. Sun, Y. Sun, Y. Sundaramoorthy, V. Sung, J. Suzuki, H. Suzuki, K. Suzuki, N. Suzuki, T. Suzuki, Y.J. Swanson, M.S. Swanton, C. Swärd, K. Swarup, G. Sweeney, S.T. Sylvester, P.W. Szatmari, Z. Szegezdi, E. Szlosarek, P.W. Taegtmeyer, H. Tafani, M. Taillebourg, E. Tait, S.W.G. Takacs-Vellai, K. Takahashi, Y. Takáts, S. Takemura, G. Takigawa, N. Talbot, N.J. Tamagno, E. Tamburini, J. Tan, C.-P. Tan, L. Tan, M.L. Tan, M. Tan, Y.-J. Tanaka, K. Tanaka, M. Tang, D. Tang, D. Tang, G. Tanida, I. Tanji, K. Tannous, B.A. Tapia, J.A. Tasset-Cuevas, I. Tatar, M. Tavassoly, I. Tavernarakis, N. Taylor, A. Taylor, G.S. Taylor, G.A. Taylor, J.P. Taylor, M.J. Tchetina, E.V. Tee, A.R. Teixeira-Clerc, F. Telang, S. Tencomnao, T. Teng, B.-B. Teng, R.-J. Terro, F. Tettamanti, G. Theiss, A.L. Theron, A.E. Thomas, K.J. Thomé, M.P. Thomes, P.G. Thorburn, A. Thorner, J. Thum, T. Thumm, M. Thurston, T.L.M. Tian, L. Till, A. Ting, J.P.-Y. Ting, J.P.Y. Titorenko, V.I. Toker, L. Toldo, S. Tooze, S.A. Topisirovic, I. Torgersen, M.L. Torosantucci, L. Torriglia, A. Torrisi, M.R. Tournier, C. Towns, R. Trajkovic, V. Travassos, L.H. Triola, G. Tripathi, D.N. Trisciuoglio, D. Troncoso, R. Trougakos, I.P. Truttmann, A.C. Tsai, K.-J. Tschan, M.P. Tseng, Y.-H. Tsukuba, T. Tsung, A. Tsvetkov, A.S. Tu, S. Tuan, H.-Y. Tucci, M. Tumbarello, D.A. Turk, B. Turk, V. Turner, R.F.B. Tveita, A.A. Tyagi, S.C. Ubukata, M. Uchiyama, Y. Udelnow, A. Ueno, T. Umekawa, M. Umemiya-Shirafuji, R. Underwood, B.R. Ungermann, C. Ureshino, R.P. Ushioda, R. Uversky, V.N. Uzcátegui, N.L. Vaccari, T. Vaccaro, M.I. Váchová, L. Vakifahmetoglu-Norberg, H. Valdor, R. Valente, E.M. Vallette, F. Valverde, A.M. Van den Berghe, G. Van Den Bosch, L. van den Brink, G.R. van der Goot, F.G. van der Klei, I.J. van der Laan, L.J.W. van Doorn, W.G. van Egmond, M. van Golen, K.L. Van Kaer, L. Campagne, M.L. Vandenabeele, P. Vandenberghe, W. Vanhorebeek, I. Varela-Nieto, I. Vasconcelos, M.H. Vasko, R. Vavvas, D.G. Vega-Naredo, I. Velasco, G. Velentzas, A.D. Velentzas, P.D. Vellai, T. Vellenga, E. Vendelbo, M.H. Venkatachalam, K. Ventura, N. Ventura, S. Veras, P.S.T. Verdier, M. Vertessy, B.G. Viale, A. Vidal, M. Vieira, H.L.A. Vierstra, R.D. Vigneswaran, N. Vij, N. Vila, M. Villar, M. Villar, V.H. Villarroya, J. Vindis, C. Viola, G. Viscomi, M.T. Vitale, G. Vogl, D.T. Voitsekhovskaja, O.V. von Haefen, C. von Schwarzenberg, K. Voth, D.E. Vouret-Craviari, V. Vuori, K. Vyas, J.M. Waeber, C. Walker, C.L. Walker, M.J. Walter, J. Wan, L. Wan, X. Wang, B. Wang, C. Wang, C.-Y. Wang, C. Wang, C. Wang, C. Wang, D. Wang, F. Wang, F. Wang, G. Wang, H.-J. Wang, H. Wang, H.-G. Wang, H. Wang, H.-D. Wang, J. Wang, J. Wang, M. Wang, M.-Q. Wang, P.-Y. Wang, P. Wang, R.C. Wang, S. Wang, T.-F. Wang, X. Wang, X.-J. Wang, X.-W. Wang, X. Wang, X. Wang, Y. Wang, Y. Wang, Y. Wang, Y.-J. Wang, Y. Wang, Y. Wang, Y.T. Wang, Y. Wang, Z.-N. Wappner, P. Ward, C. Ward, D.M.V. Warnes, G. Watada, H. Watanabe, Y. Watase, K. Weaver, T.E. Weekes, C.D. Wei, J. Weide, T. Weihl, C.C. Weindl, G. Weis, S.N. Wen, L. Wen, X. Wen, Y. Westermann, B. Weyand, C.M. White, A.R. White, E. Whitton, J.L. Whitworth, A.J. Wiels, J. Wild, F. Wildenberg, M.E. Wileman, T. Wilkinson, D.S. Wilkinson, S. Willbold, D. Williams, C. Williams, K. Williamson, P.R. Winklhofer, K.F. Witkin, S.S. Wohlgemuth, S.E. Wollert, T. Wolvetang, E.J. Wong, E. Wong, G.W. Wong, R.W. Wong, V.K.W. Woodcock, E.A. Wright, K.L. Wu, C. Wu, D. Wu, G.S. Wu, J. Wu, J. Wu, M. Wu, M. Wu, S. Wu, W.K.K. Wu, Y. Wu, Z. Xavier, C.P.R. Xavier, R.J. Xia, G.-X. Xia, T. Xia, W. Xia, Y. Xiao, H. Xiao, J. Xiao, S. Xiao, W. Xie, C.-M. Xie, Z. Xie, Z. Xilouri, M. Xiong, Y. Xu, C. Xu, C. Xu, F. Xu, H. Xu, H. Xu, J. Xu, J. Xu, J. Xu, L. Xu, X. Xu, Y. Xu, Y. Xu, Z.-X. Xu, Z. Xue, Y. Yamada, T. Yamamoto, A. Yamanaka, K. Yamashina, S. Yamashiro, S. Yan, B. Yan, B. Yan, X. Yan, Z. Yanagi, Y. Yang, D.-S. Yang, J.-M. Yang, L. Yang, M. Yang, P.-M. Yang, P. Yang, Q. Yang, W. Yang, W.Y. Yang, X. Yang, Y. Yang, Y. Yang, Z. Yang, Z. Yao, M.-C. Yao, P.J. Yao, X. Yao, Z. Yao, Z. Yasui, L.S. Ye, M. Yedvobnick, B. Yeganeh, B. Yeh, E.S. Yeyati, P.L. Yi, F. Yi, L. Yin, X.-M. Yip, C.K. Yoo, Y.-M. Yoo, Y.H. Yoon, S.-Y. Yoshida, K.-I. Yoshimori, T. Young, K.H. Yu, H. Yu, J.J. Yu, J.-T. Yu, J. Yu, L. Yu, W.H. Yu, X.-F. Yu, Z. Yuan, J. Yuan, Z.-M. Yue, B.Y.J.T. Yue, J. Yue, Z. Zacks, D.N. Zacksenhaus, E. Zaffaroni, N. Zaglia, T. Zakeri, Z. Zecchini, V. Zeng, J. Zeng, M. Zeng, Q. Zervos, A.S. Zhang, D.D. Zhang, F. Zhang, G. Zhang, G.-C. Zhang, H. Zhang, H. Zhang, H. Zhang, J. Zhang, J. Zhang, J. Zhang, J.-P. Zhang, L. Zhang, L. Zhang, L. Zhang, M.-Y. Zhang, X. Zhang, X.D. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhao, M. Zhao, W.-L. Zhao, X. Zhao, Y.G. Zhao, Y. Zhao, Y. Zhao, Y.-X. Zhao, Z. Zhao, Z.J. Zheng, D. Zheng, X.-L. Zheng, X. Zhivotovsky, B. Zhong, Q. Zhou, G.-Z. Zhou, G. Zhou, H. Zhou, S.-F. Zhou, X.-J. Zhu, H. Zhu, H. Zhu, W.-G. Zhu, W. Zhu, X.-F. Zhu, Y. Zhuang, S.-M. Zhuang, X. Ziparo, E. Zois, C.E. Zoladek, T. Zong, W.-X. Zorzano, A. Zughaier, S.M.

Published
2016

27. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Author

Klionsky, D.J. Abdelmohsen, K. Abe, A. Abedin, M.J. Abeliovich, H. Arozena, A.A. Adachi, H. Adams, C.M. Adams, P.D. Adeli, K. Adhihetty, P.J. Adler, S.G. Agam, G. Agarwal, R. Aghi, M.K. Agnello, M. Agostinis, P. Aguilar, P.V. Aguirre-Ghiso, J. Airoldi, E.M. Ait-Si-Ali, S. Akematsu, T. Akporiaye, E.T. Al-Rubeai, M. Albaiceta, G.M. Albanese, C. Albani, D. Albert, M.L. Aldudo, J. Algül, H. Alirezaei, M. Alloza, I. Almasan, A. Almonte-Beceril, M. Alnemri, E.S. Alonso, C. Altan-Bonnet, N. Altieri, D.C. Alvarez, S. Alvarez-Erviti, L. Alves, S. Amadoro, G. Amano, A. Amantini, C. Ambrosio, S. Amelio, I. Amer, A.O. Amessou, M. Amon, A. An, Z. Anania, F.A. Andersen, S.U. Andley, U.P. Andreadi, C.K. Andrieu-Abadie, N. Anel, A. Ann, D.K. Anoopkumar-Dukie, S. Antonioli, M. Aoki, H. Apostolova, N. Aquila, S. Aquilano, K. Araki, K. Arama, E. Aranda, A. Araya, J. Arcaro, A. Arias, E. Arimoto, H. Ariosa, A.R. Armstrong, J.L. Arnould, T. Arsov, I. Asanuma, K. Askanas, V. Asselin, E. Atarashi, R. Atherton, S.S. Atkin, J.D. Attardi, L.D. Auberger, P. Auburger, G. Aurelian, L. Autelli, R. Avagliano, L. Avantaggiati, M.L. Avrahami, L. Azad, N. Awale, S. Bachetti, T. Backer, J.M. Bae, D.-H. Bae, J.-S. Bae, O.-N. Bae, S.H. Baehrecke, E.H. Baek, S.-H. Baghdiguian, S. Bagniewska-Zadworna, A. Bai, H. Bai, J. Bai, X.-Y. Bailly, Y. Balaji, K.N. Balduini, W. Ballabio, A. Balzan, R. Banerjee, R. Bánhegyi, G. Bao, H. Barbeau, B. Barrachina, M.D. Barreiro, E. Bartel, B. Bartolomé, A. Bassham, D.C. Bassi, M.T. Bast, R.C., Jr. Basu, A. Batista, M.T. Batoko, H. Battino, M. Bauckman, K. Baumgarner, B.L. Bayer, K.U. Beale, R. Beaulieu, J.-F. Beck, G.R., Jr. Becker, C. Beckham, J.D. Bédard, P.-A. Bednarski, P.J. Begley, T.J. Behl, C. Behrends, C. Behrens, G.M.N. Behrns, K.E. Bejarano, E. Belaid, A. Belleudi, F. Bénard, G. Berchem, G. Bergamaschi, D. Bergami, M. Berkhout, B. Berliocchi, L. Bernard, A. Bernard, M. Bernassola, F. Bertolotti, A. Bess, A.S. Besteiro, S. Bettuzzi, S. Bhalla, S. Bhattacharyya, S. Bhutia, S.K. Biagosch, C. Bianchi, M.W. Biard-Piechaczyk, M. Billes, V. Bincoletto, C. Bingol, B. Bird, S.W. Bitoun, M. Bjedov, I. Blackstone, C. Blanc, L. Blanco, G.A. Blomhoff, H.K. Boada-Romero, E. Böckler, S. Boes, M. Boesze-Battaglia, K. Boise, L.H. Bolino, A. Boman, A. Bonaldo, P. Bordi, M. Bosch, J. Botana, L.M. Botti, J. Bou, G. Bouché, M. Bouchecareilh, M. Boucher, M.-J. Boulton, M.E. Bouret, S.G. Boya, P. Boyer-Guittaut, M. Bozhkov, P.V. Brady, N. Braga, V.M.M. Brancolini, C. Braus, G.H. Bravo-San-Pedro, J.M. Brennan, L.A. Bresnick, E.H. Brest, P. Bridges, D. Bringer, M.-A. Brini, M. Brito, G.C. Brodin, B. Brookes, P.S. Brown, E.J. Brown, K. Broxmeyer, H.E. Bruhat, A. Brum, P.C. Brumell, J.H. Brunetti-Pierri, N. Bryson-Richardson, R.J. Buch, S. Buchan, A.M. Budak, H. Bulavin, D.V. Bultman, S.J. Bultynck, G. Bumbasirevic, V. Burelle, Y. Burke, R.E. Burmeister, M. Bütikofer, P. Caberlotto, L. Cadwell, K. Cahova, M. Cai, D. Cai, J. Cai, Q. Calatayud, S. Camougrand, N. Campanella, M. Campbell, G.R. Campbell, M. Campello, S. Candau, R. Caniggia, I. Cantoni, L. Cao, L. Caplan, A.B. Caraglia, M. Cardinali, C. Cardoso, S.M. Carew, J.S. Carleton, L.A. Carlin, C.R. Carloni, S. Carlsson, S.R. Carmona-Gutierrez, D. Carneiro, L.A.M. Carnevali, O. Carra, S. Carrier, A. Carroll, B. Casas, C. Casas, J. Cassinelli, G. Castets, P. Castro-Obregon, S. Cavallini, G. Ceccherini, I. Cecconi, F. Cederbaum, A.I. Ceña, V. Cenci, S. Cerella, C. Cervia, D. Cetrullo, S. Chaachouay, H. Chae, H.-J. Chagin, A.S. Chai, C.-Y. Chakrabarti, G. Chamilos, G. Chan, E.Y.W. Chan, M.T.V. Chandra, D. Chandra, P. Chang, C.-P. Chang, R.C.-C. Chang, T.Y. Chatham, J.C. Chatterjee, S. Chauhan, S. Che, Y. Cheetham, M.E. Cheluvappa, R. Chen, C.-J. Chen, G. Chen, G.-C. Chen, G. Chen, H. Chen, J.W. Chen, J.-K. Chen, M. Chen, M. Chen, P. Chen, Q. Chen, Q. Chen, S.-D. Chen, S. Chen, S.S.-L. Chen, W. Chen, W.-J. Chen, W.Q. Chen, W. Chen, X. Chen, Y.-H. Chen, Y.-G. Chen, Y. Chen, Y. Chen, Y. Chen, Y.-J. Chen, Y.-Q. Chen, Y. Chen, Z. Chen, Z. Cheng, A. Cheng, C.H.K. Cheng, H. Cheong, H. Cherry, S. Chesney, J. Cheung, C.H.A. Chevet, E. Chi, H.C. Chi, S.-G. Chiacchiera, F. Chiang, H.-L. Chiarelli, R. Chiariello, M. Chieppa, M. Chin, L.-S. Chiong, M. Chiu, G.N.C. Cho, D.-H. Cho, S.-G. Cho, W.C. Cho, Y.-Y. Cho, Y.-S. Choi, A.M.K. Choi, E.-J. Choi, E.-K. Choi, J. Choi, M.E. Choi, S.-I. Chou, T.-F. Chouaib, S. Choubey, D. Choubey, V. Chow, K.-C. Chowdhury, K. Chu, C.T. Chuang, T.-H. Chun, T. Chung, H. Chung, T. Chung, Y.-L. Chwae, Y.-J. Cianfanelli, V. Ciarcia, R. Ciechomska, I.A. Ciriolo, M.R. Cirone, M. Claerhout, S. Clague, M.J. Clària, J. Clarke, P.G.H. Clarke, R. Clementi, E. Cleyrat, C. Cnop, M. Coccia, E.M. Cocco, T. Codogno, P. Coers, J. Cohen, E.E.W. Colecchia, D. Coletto, L. Coll, N.S. Colucci-Guyon, E. Comincini, S. Condello, M. Cook, K.L. Coombs, G.H. Cooper, C.D. Cooper, J.M. Coppens, I. Corasaniti, M.T. Corazzari, M. Corbalan, R. Corcelle-Termeau, E. Cordero, M.D. Corral-Ramos, C. Corti, O. Cossarizza, A. Costelli, P. Costes, S. Cotman, S.L. Coto-Montes, A. Cottet, S. Couve, E. Covey, L.R. Cowart, L.A. Cox, J.S. Coxon, F.P. Coyne, C.B. Cragg, M.S. Craven, R.J. Crepaldi, T. Crespo, J.L. Criollo, A. Crippa, V. Cruz, M.T. Cuervo, A.M. Cuezva, J.M. Cui, T. Cutillas, P.R. Czaja, M.J. Czyzyk-Krzeska, M.F. Dagda, R.K. Dahmen, U. Dai, C. Dai, W. Dai, Y. Dalby, K.N. Valle, L.D. Dalmasso, G. D'amelio, M. Damme, M. Darfeuille-Michaud, A. Dargemont, C. Darley-Usmar, V.M. Dasarathy, S. Dasgupta, B. Dash, S. Dass, C.R. Davey, H.M. Davids, L.M. Dávila, D. Davis, R.J. Dawson, T.M. Dawson, V.L. Daza, P. de Belleroche, J. de Figueiredo, P. de Figueiredo, R.C.B.Q. de la Fuente, J. De Martino, L. De Matteis, A. De Meyer, G.R.Y. De Milito, A. De Santi, M. de Souza, W. De Tata, V. De Zio, D. Debnath, J. Dechant, R. Decuypere, J.-P. Deegan, S. Dehay, B. Del Bello, B. Del Re, D.P. Delage-Mourroux, R. Delbridge, L.M.D. Deldicque, L. Delorme-Axford, E. Deng, Y. Dengjel, J. Denizot, M. Dent, P. Der, C.J. Deretic, V. Derrien, B. Deutsch, E. Devarenne, T.P. Devenish, R.J. Di Bartolomeo, S. Di Daniele, N. Di Domenico, F. Di Nardo, A. Di Paola, S. Di Pietro, A. Di Renzo, L. Di Antonio, A. Díaz-Araya, G. Díaz-Laviada, I. Diaz-Meco, M.T. Diaz-Nido, J. Dickey, C.A. Dickson, R.C. Diederich, M. Digard, P. Dikic, I. Dinesh-Kumar, S.P. Ding, C. Ding, W.-X. Ding, Z. Dini, L. Distler, J.H.W. Diwan, A. Djavaheri-Mergny, M. Dmytruk, K. Dobson, R.C.J. Doetsch, V. Dokladny, K. Dokudovskaya, S. Donadelli, M. Dong, X.C. Dong, X. Dong, Z. Donohue, T.M., Jr. Donohue-Jr, T.M. Doran, K.S. D'orazi, G. Dorn, G.W., II Dosenko, V. Dridi, S. Drucker, L. Du, J. Du, L.-L. Du, L. du Toit, A. Dua, P. Duan, L. Duann, P. Dubey, V.K. Duchen, M.R. Duchosal, M.A. Duez, H. Dugail, I. Dumit, V.I. Duncan, M.C. Dunlop, E.A. Dunn, W.A., Jr. Dupont, N. Dupuis, L. Durán, R.V. Durcan, T.M. Duvezin-Caubet, S. Duvvuri, U. Eapen, V. Ebrahimi-Fakhari, D. Echard, A. Eckhart, L. Edelstein, C.L. Edinger, A.L. Eichinger, L. Eisenberg, T. Eisenberg-Lerner, A. Eissa, N.T. El-Deiry, W.S. El-Khoury, V. Elazar, Z. Eldar-Finkelman, H. Elliott, C.J.H. Emanuele, E. Emmenegger, U. Engedal, N. Engelbrecht, A.-M. Engelender, S. Enserink, J.M. Erdmann, R. Erenpreisa, J. Eri, R. Eriksen, J.L. Erman, A. Escalante, R. Eskelinen, E.-L. Espert, L. Esteban-Martínez, L. Evans, T.J. Fabri, M. Fabrias, G. Fabrizi, C. Facchiano, A. Færgeman, N.J. Faggioni, A. Fairlie, W.D. Fan, C. Fan, D. Fan, J. Fang, S. Fanto, M. Fanzani, A. Farkas, T. Faure, M. Favier, F.B. Fearnhead, H. Federici, M. Fei, E. Felizardo, T.C. Feng, H. Feng, Y. Feng, Y. Ferguson, T.A. Fernández, Á.F. Fernandez-Barrena, M.G. Fernandez-Checa, J.C. Fernández-López, A. Fernandez-Zapico, M.E. Feron, O. Ferraro, E. Ferreira-Halder, C.V. Fesus, L. Feuer, R. Fiesel, F.C. Filippi-Chiela, E.C. Filomeni, G. Fimia, G.M. Fingert, J.H. Finkbeiner, S. Finkel, T. Fiorito, F. Fisher, P.B. Flajolet, M. Flamigni, F. Florey, O. Florio, S. Floto, R.A. Folini, M. Follo, C. Fon, E.A. Fornai, F. Fortunato, F. Fraldi, A. Franco, R. Francois, A. François, A. Frankel, L.B. Fraser, I.D.C. Frey, N. Freyssenet, D.G. Frezza, C. Friedman, S.L. Frigo, D.E. Fu, D. Fuentes, J.M. Fueyo, J. Fujitani, Y. Fujiwara, Y. Fujiya, M. Fukuda, M. Fulda, S. Fusco, C. Gabryel, B. Gaestel, M. Gailly, P. Gajewska, M. Galadari, S. Galili, G. Galindo, I. Galindo, M.F. Galliciotti, G. Galluzzi, L. Galluzzi, L. Galy, V. Gammoh, N. Gandy, S. Ganesan, A.K. Ganesan, S. Ganley, I.G. Gannagé, M. Gao, F.-B. Gao, F. Gao, J.-X. Nannig, L.G. Véscovi, E.G. Garcia-Macía, M. Garcia-Ruiz, C. Garg, A.D. Garg, P.K. Gargini, R. Gassen, N.C. Gatica, D. Gatti, E. Gavard, J. Gavathiotis, E. Ge, L. Ge, P. Ge, S. Gean, P.-W. Gelmetti, V. Genazzani, A.A. Geng, J. Genschik, P. Gerner, L. Gestwicki, J.E. Gewirtz, D.A. Ghavami, S. Ghigo, E. Ghosh, D. Giammarioli, A.M. Giampieri, F. Giampietri, C. Giatromanolaki, A. Gibbings, D.J. Gibellini, L. Gibson, S.B. Ginet, V. Giordano, A. Giorgini, F. Giovannetti, E. Girardin, S.E. Gispert, S. Giuliano, S. Gladson, C.L. Glavic, A. Gleave, M. Godefroy, N. Gogal, R.M., Jr. Gokulan, K. Goldman, G.H. Goletti, D. Goligorsky, M.S. Gomes, A.V. Gomes, L.C. Gomez, H. Gomez-Manzano, C. Gómez-Sánchez, R. Gonçalves, D.A.P. Goncu, E. Gong, Q. Gongora, C. Gonzalez, C.B. Gonzalez-Alegre, P. Gonzalez-Cabo, P. González-Polo, R.A. Goping, I.S. Gorbea, C. Gorbunov, N.V. Goring, D.R. Gorman, A.M. Gorski, S.M. Goruppi, S. Goto-Yamada, S. Gotor, C. Gottlieb, R.A. Gozes, I. Gozuacik, D. Graba, Y. Graef, M. Granato, G.E. Grant, G.D. Grant, S. Gravina, G.L. Green, D.R. Greenhough, A. Greenwood, M.T. Grimaldi, B. Gros, F. Grose, C. Groulx, J.-F. Gruber, F. Grumati, P. Grune, T. Guan, J.-L. Guan, K.-L. Guerra, B. Guillen, C. Gulshan, K. Gunst, J. Guo, C. Guo, L. Guo, M. Guo, W. Guo, X.-G. Gust, A.A. Gustafsson, Å.B. Gutierrez, E. Gutierrez, M.G. Gwak, H.-S. Haas, A. Haber, J.E. Hadano, S. Hagedorn, M. Hahn, D.R. Halayko, A.J. Hamacher-Brady, A. Hamada, K. Hamai, A. Hamann, A. Hamasaki, M. Hamer, I. Hamid, Q. Hammond, E.M. Han, F. Han, W. Handa, J.T. Hanover, J.A. Hansen, M. Harada, M. Harhaji-Trajkovic, L. Harper, J.W. Harrath, A.H. Harris, A.L. Harris, J. Hasler, U. Hasselblatt, P. Hasui, K. Hawley, R.G. Hawley, T.S. He, C. He, C.Y. He, F. He, G. He, R.-R. He, X.-H. He, Y.-W. He, Y.-Y. Heath, J.K. Hébert, M.-J. Heinzen, R.A. Helgason, G.V. Hensel, M. Henske, E.P. Her, C. Herman, P.K. Hernández, A. Hernandez, C. Hernández-Tiedra, S. Hetz, C. Hiesinger, P.R. Higaki, K. Hilfiker, S. Hill, B.G. Hill, J.A. Hill, W.D. Hino, K. Hofius, D. Hofman, P. Höglinger, G.U. Höhfeld, J. Holz, M.K. Hong, Y. Hood, D.A. Hoozemans, J.J.M. Hoppe, T. Hsu, C. Hsu, C.-Y. Hsu, L.-C. Hu, D. Hu, G. Hu, H.-M. Hu, H. Hu, M.C. Hu, Y.-C. Hu, Z.-W. Hua, F. Hua, Y. Huang, C. Huang, H.-L. Huang, K.-H. Huang, K.-Y. Huang, S. Huang, S. Huang, W.-P. Huang, Y.-R. Huang, Y. Huang, Y. Huber, T.B. Huebbe, P. Huh, W.-K. Hulmi, J.J. Hur, G.M. Hurley, J.H. Husak, Z. Hussain, S.N.A. Hussain, S. Hwang, J.J. Hwang, S. Hwang, T.I.S. Ichihara, A. Imai, Y. Imbriano, C. Inomata, M. Into, T. Iovane, V. Iovanna, J.L. Iozzo, R.V. Ip, N.Y. Irazoqui, J.E. Iribarren, P. Isaka, Y. Isakovic, A.J. Ischiropoulos, H. Isenberg, J.S. Ishaq, M. Ishida, H. Ishii, I. Ishmael, J.E. Isidoro, C. Isobe, K.-I. Isono, E. Issazadeh-Navikas, S. Itahana, K. Itakura, E. Ivanov, A.I. Iyer, A.K.V. Izquierdo, J.M. Izumi, Y. Izzo, V. Jäättelä, M. Jaber, N. Jackson, D.J. Jackson, W.T. Jacob, T.G. Jacques, T.S. Jagannath, C. Jain, A. Jana, N.R. Jang, B.K. Jani, A. Janji, B. Jannig, P.R. Jansson, P.J. Jean, S. Jendrach, M. Jeon, J.-H. Jessen, N. Jeung, E.-B. Jia, K. Jia, L. Jiang, H. Jiang, H. Jiang, L. Jiang, T. Jiang, X. Jiang, X. Jiang, Y. Jiang, Y. Jiménez, A. Jin, C. Jin, H. Jin, L. Jin, M. Jin, S. Jinwal, U.K. Jo, E.-K. Johansen, T. Johnson, D.E. Johnson, G.V.W. Johnson, J.D. Jonasch, E. Jones, C. Joosten, L.A.B. Jordan, J. Joseph, A.-M. Joseph, B. Joubert, A.M. Ju, D. Ju, J. Juan, H.-F. Juenemann, K. Juhász, G. Jung, H.S. Jung, J.U. Jung, Y.-K. Jungbluth, H. Justice, M.J. Jutten, B. Kaakoush, N.O. Kaarniranta, K. Kaasik, A. Kabuta, T. Kaeffer, B. Kågedal, K. Kahana, A. Kajimura, S. Kakhlon, O. Kalia, M. Kalvakolanu, D.V. Kamada, Y. Kambas, K. Kaminskyy, V.O. Kampinga, H.H. Kandouz, M. Kang, C. Kang, R. Kang, T.-C. Kanki, T. Kanneganti, T.-D. Kanno, H. Kanthasamy, A.G. Kantorow, M. Kaparakis-Liaskos, M. Kapuy, O. Karantza, V. Karim, M.R. Karmakar, P. Kaser, A. Kaushik, S. Kawula, T. Kaynar, A.M. Ke, P.-Y. Ke, Z.-J. Kehrl, J.H. Keller, K.E. Kemper, J.K. Kenworthy, A.K. Kepp, O. Kern, A. Kesari, S. Kessel, D. Ketteler, R. Kettelhut, I.C. Khambu, B. Khan, M.M. Khandelwal, V.K.M. Khare, S. Kiang, J.G. Kiger, A.A. Kihara, A. Kim, A.L. Kim, C.H. Kim, D.R. Kim, D.-H. Kim, E.K. Kim, H.Y. Kim, H.-R. Kim, J.-S. Kim, J.H. Kim, J.C. Kim, J.H. Kim, K.W. Kim, M.D. Kim, M.-M. Kim, P.K. Kim, S.W. Kim, S.-Y. Kim, Y.-S. Kim, Y. Kimchi, A. Kimmelman, A.C. Kimura, T. King, J.S. Kirkegaard, K. Kirkin, V. Kirshenbaum, L.A. Kishi, S. Kitajima, Y. Kitamoto, K. Kitaoka, Y. Kitazato, K. Kley, R.A. Klimecki, W.T. Klinkenberg, M. Klucken, J. Knævelsrud, H. Knecht, E. Knuppertz, L. Ko, J.-L. Kobayashi, S. Koch, J.C. Koechlin-Ramonatxo, C. Koenig, U. Koh, Y.H. Köhler, K. Kohlwein, S.D. Koike, M. Komatsu, M. Kominami, E. Kong, D. Kong, H.J. Konstantakou, E.G. Kopp, B.T. Korcsmaros, T. Korhonen, L. Korolchuk, V.I. Koshkina, N.V. Kou, Y. Koukourakis, M.I. Koumenis, C. Kovács, A.L. Kovács, T. Kovacs, W.J. Koya, D. Kraft, C. Krainc, D. Kramer, H. Kravic-Stevovic, T. Krek, W. Kretz-Remy, C. Krick, R. Krishnamurthy, M. Kriston-Vizi, J. Kroemer, G. Kruer, M.C. Kruger, R. Ktistakis, N.T. Kuchitsu, K. Kuhn, C. Kumar, A.P. Kumar, A. Kumar, A. Kumar, D. Kumar, D. Kumar, R. Kumar, S. Kundu, M. Kung, H.-J. Kuno, A. Kuo, S.-H. Kuret, J. Kurz, T. Kwok, T. Kwon, T.K. Kwon, Y.T. Kyrmizi, I. La Spada, A.R. Lafont, F. Lahm, T. Lakkaraju, A. Lam, T. Lamark, T. Lancel, S. Landowski, T.H. Lane, D.J.R. Lane, J.D. Lanzi, C. Lapaquette, P. Lapierre, L.R. Laporte, J. Laukkarinen, J. Laurie, G.W. Lavandero, S. Lavie, L. Lavoie, M.J. Law, B.Y.K. Law, H.K.-W. Law, K.B. Layfield, R. Lazo, P.A. Le Cam, L. Le Roch, K.G. Le Stunff, H. Leardkamolkarn, V. Lecuit, M. Lee, B.-H. Lee, C.-H. Lee, E.F. Lee, G.M. Lee, H.-J. Lee, H. Lee, J.K. Lee, J. Lee, J.-H. Lee, J.H. Lee, M. Lee, M.-S. Lee, P.J. Lee, S.W. Lee, S.-J. Lee, S.-J. Lee, S.Y. Lee, S.H. Lee, S.S. Lee, S.-J. Lee, S. Lee, Y.-R. Lee, Y.J. Lee, Y.H. Leeuwenburgh, C. Lefort, S. Legouis, R. Lei, J. Lei, Q.-Y. Leib, D.A. Leibowitz, G. Lekli, I. Lemaire, S.D. Lemasters, J.J. Lemberg, M.K. Lemoine, A. Leng, S. Lenz, G. Lenzi, P. Lerman, L.O. Barbato, D.L. Leu, J.I.J. Leung, H.Y. Levine, B. Lewis, P.A. Lezoualch, F. Li, C. Li, F. Li, F.-J. Li, J. Li, K. Li, L. Li, M. Li, Q. Li, R. Li, S. Li, W. Li, X. Li, Y. Lian, J. Liang, C. Liang, Q. Liao, Y. Liberal, J. Liberski, P.P. Lie, P. Lieberman, A.P. Lim, H.J. Lim, K.-L. Lim, K. Lima, R.T. Lin, C.-S. Lin, C.-F. Lin, F. Lin, F. Lin, F.-C. Lin, K. Lin, K.-H. Lin, P.-H. Lin, T. Lin, W.-W. Lin, Y.-S. Lin, Y. Linden, R. Lindholm, D. Lindqvist, L.M. Lingor, P. Linkermann, A. Liotta, L.A. Lipinski, M.M. Lira, V.A. Lisanti, M.P. Liton, P.B. Liu, B. Liu, C. Liu, C.-F. Liu, F. Liu, H.-J. Liu, J. Liu, J.-J. Liu, J.-L. Liu, K. Liu, L. Liu, L. Liu, Q. Liu, R.-Y. Liu, S. Liu, S. Liu, W. Liu, X.-D. Liu, X. Liu, X.-H. Liu, X. Liu, X. Liu, X. Liu, Y. Liu, Y. Liu, Z. Liu, Z. Liuzzi, J.P. Lizard, G. Ljujic, M. Lodhi, I.J. Logue, S.E. Lokeshwar, B.L. Long, Y.C. Lonial, S. Loos, B. López-Otín, C. López-Vicario, C. Lorente, M. Lorenzi, P.L. Lõrincz, P. Los, M. Lotze, M.T. Lovat, P.E. Lu, B. Lu, B. Lu, J. Lu, Q. Lu, S.-M. Lu, S. Lu, Y. Luciano, F. Luckhart, S. Lucocq, J.M. Ludovico, P. Lugea, A. Lukacs, N.W. Lum, J.J. Lund, A.H. Luo, H. Luo, J. Luo, S. Luparello, C. Lyons, T. Ma, J. Ma, Y. Ma, Y. Ma, Z. Machado, J. Machado-Santelli, G.M. Macian, F. MacIntosh, G.C. MacKeigan, J.P. Macleod, K.F. MacMicking, J.D. MacMillan-Crow, L.A. Madeo, F. Madesh, M. Madrigal-Matute, J. Maeda, A. Maeda, T. Maegawa, G. Maellaro, E. Maes, H. Magariños, M. Maiese, K. Maiti, T.K. Maiuri, L. Maiuri, M.C. Maki, C.G. Malli, R. Malorni, W. Maloyan, A. Mami-Chouaib, F. Man, N. Mancias, J.D. Mandelkow, E.-M. Mandell, M.A. Manfredi, A.A. Manié, S.N. Manzoni, C. Mao, K. Mao, Z. Mao, Z.-W. Marambaud, P. Marconi, A.M. Marelja, Z. Marfe, G. Margeta, M. Margittai, E. Mari, M. Mariani, F.V. Marin, C. Marinelli, S. Mariño, G. Markovic, I. Marquez, R. Martelli, A.M. Martens, S. Martin, K.R. Martin, S.J. Martin, S. Martin-Acebes, M.A. Martín-Sanz, P. Martinand-Mari, C. Martinet, W. Martinez, J. Martinez-Lopez, N. Martinez-Outschoorn, U. Martínez-Velázquez, M. Martinez-Vicente, M. Martins, W.K. Mashima, H. Mastrianni, J.A. Matarese, G. Matarrese, P. Mateo, R. Matoba, S. Matsumoto, N. Matsushita, T. Matsuura, A. Matsuzawa, T. Mattson, M.P. Matus, S. Maugeri, N. Mauvezin, C. Mayer, A. Maysinger, D. Mazzolini, G.D. McBrayer, M.K. McCall, K. McCormick, C. McInerney, G.M. McIver, S.C. McKenna, S. McMahon, J.J. McNeish, I.A. Mechta-Grigoriou, F. Medema, J.P. Medina, D.L. Megyeri, K. Mehrpour, M. Mehta, J.L. Mei, Y. Meier, U.-C. Meijer, A.J. Meléndez, A. Melino, G. Melino, S. de Melo, E.J.T. Mena, M.A. Meneghini, M.D. Menendez, J.A. Menezes, R. Meng, L. Meng, L.-H. Meng, S. Menghini, R. Menko, A.S. Menna-Barreto, R.F.S. Menon, M.B. Meraz-Ríos, M.A. Merla, G. Merlini, L. Merlot, A.M. Meryk, A. Meschini, S. Meyer, J.N. Mi, M.-T. Miao, C.-Y. Micale, L. Michaeli, S. Michiels, C. Migliaccio, A.R. Mihailidou, A.S. Mijaljica, D. Mikoshiba, K. Milan, E. Miller-Fleming, L. Mills, G.B. Mills, I.G. Minakaki, G. Minassian, B.A. Ming, X.-F. Minibayeva, F. Minina, E.A. Mintern, J.D. Minucci, S. Miranda-Vizuete, A. Mitchell, C.H. Miyamoto, S. Miyazawa, K. Mizushima, N. Mnich, K. Mograbi, B. Mohseni, S. Moita, L.F. Molinari, M. Molinari, M. Møller, A.B. Mollereau, B. Mollinedo, F. Mongillo, M. Monick, M.M. Montagnaro, S. Montell, C. Moore, D.J. Moore, M.N. Mora-Rodriguez, R. Moreira, P.I. Morel, E. Morelli, M.B. Moreno, S. Morgan, M.J. Moris, A. Moriyasu, Y. Morrison, J.L. Morrison, L.A. Morselli, E. Moscat, J. Moseley, P.L. Mostowy, S. Motori, E. Mottet, D. Mottram, J.C. Moussa, C.E.-H. Mpakou, V.E. Mukhtar, H. Levy, J.M.M. Muller, S. Muñoz-Moreno, R. Muñoz-Pinedo, C. Münz, C. Murphy, M.E. Murray, J.T. Murthy, A. Mysorekar, I.U. Nabi, I.R. Nabissi, M. Nader, G.A. Nagahara, Y. Nagai, Y. Nagata, K. Nagelkerke, A. Nagy, P. Naidu, S.R. Nair, S. Nakano, H. Nakatogawa, H. Nanjundan, M. Napolitano, G. Naqvi, N.I. Nardacci, R. Narendra, D.P. Narita, M. Nascimbeni, A.C. Natarajan, R. Navegantes, L.C. Nawrocki, S.T. Nazarko, T.Y. Nazarko, V.Y. Neill, T. Neri, L.M. Netea, M.G. Netea-Maier, R.T. Neves, B.M. Ney, P.A. Nezis, I.P. Nguyen, H.T.T. Nguyen, H.P. Nicot, A.-S. Nilsen, H. Nilsson, P. Nishimura, M. Nishino, I. Niso-Santano, M. Niu, H. Nixon, R.A. Njar, V.C.O. Noda, T. Noegel, A.A. Nolte, E.M. Norberg, E. Norga, K.K. Noureini, S.K. Notomi, S. Notterpek, L. Nowikovsky, K. Nukina, N. Nürnberger, T. O'donnell, V.B. O'donovan, T. O'dwyer, P.J. Oehme, I. Oeste, C.L. Ogawa, M. Ogretmen, B. Ogura, Y. Oh, Y.J. Ohmuraya, M. Ohshima, T. Ojha, R. Okamoto, K. Okazaki, T. Oliver, F.J. Ollinger, K. Olsson, S. Orban, D.P. Ordonez, P. Orhon, I. Orosz, L. O'rourke, E.J. Orozco, H. Ortega, A.L. Ortona, E. Osellame, L.D. Oshima, J. Oshima, S. Osiewacz, H.D. Otomo, T. Otsu, K. Ou, J.-H.J. Outeiro, T.F. Ouyang, D.-Y. Ouyang, H. Overholtzer, M. Ozbun, M.A. Ozdinler, P.H. Ozpolat, B. Pacelli, C. Paganetti, P. Page, G. Pages, G. Pagnini, U. Pajak, B. Pak, S.C. Pakos-Zebrucka, K. Pakpour, N. Palková, Z. Palladino, F. Pallauf, K. Pallet, N. Palmieri, M. Paludan, S.R. Palumbo, C. Palumbo, S. Pampliega, O. Pan, H. Pan, W. Panaretakis, T. Pandey, A. Pantazopoulou, A. Papackova, Z. Papademetrio, D.L. Papassideri, I. Papini, A. Parajuli, N. Pardo, J. Parekh, V.V. Parenti, G. Park, J.-I. Park, J. Park, O.K. Parker, R. Parlato, R. Parys, J.B. Parzych, K.R. Pasquet, J.-M. Pasquier, B. Pasumarthi, K.B.S. Patterson, C. Pattingre, S. Pattison, S. Pause, A. Pavenstädt, H. Pavone, F. Pedrozo, Z. Peña, F.J. Peñalva, M.A. Pende, M. Peng, J. Penna, F. Penninger, J.M. Pensalfini, A. Pepe, S. Pereira, G.J.S. Pereira, P.C. de la Cruz, V.P. Pérez-Pérez, M.E. Pérez-Rodríguez, D. Pérez-Sala, D. Perier, C. Perl, A. Perlmutter, D.H. Perrotta, I. Pervaiz, S. Pesonen, M. Pessin, J.E. Peters, G.J. Petersen, M. Petrache, I. Petrof, B.J. Petrovski, G. Phang, J.M. Piacentini, M. Pierdominici, M. Pierre, P. Pierrefite-Carle, V. Pietrocola, F. Pimentel-Muiños, F.X. Pinar, M. Pineda, B. Pinkas-Kramarski, R. Pinti, M. Pinton, P. Piperdi, B. Piret, J.M. Platanias, L.C. Platta, H.W. Plowey, E.D. Pöggeler, S. Poirot, M. Polčic, P. Poletti, A. Poon, A.H. Popelka, H. Popova, B. Poprawa, I. Poulose, S.M. Poulton, J. Powers, S.K. Powers, T. Pozuelo-Rubio, M. Prak, K. Prange, R. Prescott, M. Priault, M. Prince, S. Proia, R.L. Proikas-Cezanne, T. Prokisch, H. Promponas, V.J. Przyklenk, K. Puertollano, R. Pugazhenthi, S. Puglielli, L. Pujol, A. Puyal, J. Pyeon, D. Qi, X. Qian, W.-B. Qin, Z.-H. Qiu, Y. Qu, Z. Quadrilatero, J. Quinn, F. Raben, N. Rabinowich, H. Radogna, F. Ragusa, M.J. Rahmani, M. Raina, K. Ramanadham, S. Ramesh, R. Rami, A. Randall-Demllo, S. Randow, F. Rao, H. Rao, V.A. Rasmussen, B.B. Rasse, T.M. Ratovitski, E.A. Rautou, P.-E. Ray, S.K. Razani, B. Reed, B.H. Reggiori, F. Rehm, M. Reichert, A.S. Rein, T. Reiner, D.J. Reits, E. Ren, J. Ren, X. Renna, M. Reusch, J.E.B. Revuelta, J.L. Reyes, L. Rezaie, A.R. Richards, R.I. Richardson, R. Richetta, C. Riehle, M.A. Rihn, B.H. Rikihisa, Y. Riley, B.E. Rimbach, G. Rippo, M.R. Ritis, K. Rizzi, F. Rizzo, E. Roach, P.J. Robbins, J. Roberge, M. Roca, G. Roccheri, M.C. Rocha, S. Rodrigues, C.M.P. Rodríguez, C.I. de Cordoba, S.R. Rodriguez-Muela, N. Roelofs, J. Rogov, V.V. Rohn, T.T. Rohrer, B. Romanelli, D. Romani, L. Romano, P.S. Roncero, M.I.G. Rosa, J.L. Rosello, A. Rosen, K.V. Rosenstiel, P. Rost-Roszkowska, M. Roth, K.A. Roué, G. Rouis, M. Rouschop, K.M. Ruan, D.T. Ruano, D. Rubinsztein, D.C. Rucker, E.B., III Rudich, A. Rudolf, E. Rudolf, R. Ruegg, M.A. Ruiz-Roldan, C. Ruparelia, A.A. Rusmini, P. Russ, D.W. Russo, G.L. Russo, G. Russo, R. Rusten, T.E. Ryabovol, V. Ryan, K.M. Ryter, S.W. Sabatini, D.M. Sacher, M. Sachse, C. Sack, M.N. Sadoshima, J. Saftig, P. Sagi-Eisenberg, R. Sahni, S. Saikumar, P. Saito, T. Saitoh, T. Sakakura, K. Sakoh-Nakatogawa, M. Sakuraba, Y. Salazar-Roa, M. Salomoni, P. Saluja, A.K. Salvaterra, P.M. Salvioli, R. Samali, A. Sanchez, A.M.J. Sánchez-Alcázar, J.A. Sanchez-Prieto, R. Sandri, M. Sanjuan, M.A. Santaguida, S. Santambrogio, L. Santoni, G. Dos Santos, C.N. Saran, S. Sardiello, M. Sargent, G. Sarkar, P. Sarkar, S. Sarrias, M.R. Sarwal, M.M. Sasakawa, C. Sasaki, M. Sass, M. Sato, K. Sato, M. Satriano, J. Savaraj, N. Saveljeva, S. Schaefer, L. Schaible, U.E. Scharl, M. Schatzl, H.M. Schekman, R. Scheper, W. Schiavi, A. Schipper, H.M. Schmeisser, H. Schmidt, J. Schmitz, I. Schneider, B.E. Schneider, E.M. Schneider, J.L. Schon, E.A. Schönenberger, M.J. Schönthal, A.H. Schorderet, D.F. Schröder, B. Schuck, S. Schulze, R.J. Schwarten, M. Schwarz, T.L. Sciarretta, S. Scotto, K. Scovassi, A.I. Screaton, R.A. Screen, M. Seca, H. Sedej, S. Segatori, L. Segev, N. Seglen, P.O. Seguí-Simarro, J.M. Segura-Aguilar, J. Seiliez, I. Seki, E. Sell, C. Semenkovich, C.F. Semenza, G.L. Sen, U. Serra, A.L. Serrano-Puebla, A. Sesaki, H. Setoguchi, T. Settembre, C. Shacka, J.J. Shajahan-Haq, A.N. Shapiro, I.M. Sharma, S. She, H. Shen, C.-K.J. Shen, C.-C. Shen, H.-M. Shen, S. Shen, W. Sheng, R. Sheng, X. Sheng, Z.-H. Shepherd, T.G. Shi, J. Shi, Q. Shi, Q. Shi, Y. Shibutani, S. Shibuya, K. Shidoji, Y. Shieh, J.-J. Shih, C.-M. Shimada, Y. Shimizu, S. Shin, D.W. Shinohara, M.L. Shintani, M. Shintani, T. Shioi, T. Shirabe, K. Shiri-Sverdlov, R. Shirihai, O. Shore, G.C. Shu, C.-W. Shukla, D. Sibirny, A.A. Sica, V. Sigurdson, C.J. Sigurdsson, E.M. Sijwali, P.S. Sikorska, B. Silveira, W.A. Silvente-Poirot, S. Silverman, G.A. Simak, J. Simmet, T. Simon, A.K. Simon, H.-U. Simone, C. Simons, M. Simonsen, A. Singh, R. Singh, S.V. Singh, S.K. Sinha, D. Sinha, S. Sinicrope, F.A. Sirko, A. Sirohi, K. Sishi, B.J.N. Sittler, A. Siu, P.M. Sivridis, E. Skwarska, A. Slack, R. Slaninová, I. Slavov, N. Smaili, S.S. Smalley, K.S.M. Smith, D.R. Soenen, S.J. Soleimanpour, S.A. Solhaug, A. Somasundaram, K. Son, J.H. Sonawane, A. Song, C. Song, F. Song, H.K. Song, J.-X. Song, W. Soo, K.Y. Sood, A.K. Soong, T.W. Soontornniyomkij, V. Sorice, M. Sotgia, F. Soto-Pantoja, D.R. Sotthibundhu, A. Sousa, M.J. Spaink, H.P. Span, P.N. Spang, A. Sparks, J.D. Speck, P.G. Spector, S.A. Spies, C.D. Springer, W. Clair, D.S. Stacchiotti, A. Staels, B. Stang, M.T. Starczynowski, D.T. Starokadomskyy, P. Steegborn, C. Steele, J.W. Stefanis, L. Steffan, J. Stellrecht, C.M. Stenmark, H. Stepkowski, T.M. Stern, S.T. Stevens, C. Stockwell, B.R. Stoka, V. Storchova, Z. Stork, B. Stratoulias, V. Stravopodis, D.J. Strnad, P. Strohecker, A.M. Ström, A.-L. Stromhaug, P. Stulik, J. Su, Y.-X. Su, Z. Subauste, C.S. Subramaniam, S. Sue, C.M. Suh, S.W. Sui, X. Sukseree, S. Sulzer, D. Sun, F.-L. Sun, J. Sun, J. Sun, S.-Y. Sun, Y. Sun, Y. Sun, Y. Sundaramoorthy, V. Sung, J. Suzuki, H. Suzuki, K. Suzuki, N. Suzuki, T. Suzuki, Y.J. Swanson, M.S. Swanton, C. Swärd, K. Swarup, G. Sweeney, S.T. Sylvester, P.W. Szatmari, Z. Szegezdi, E. Szlosarek, P.W. Taegtmeyer, H. Tafani, M. Taillebourg, E. Tait, S.W.G. Takacs-Vellai, K. Takahashi, Y. Takáts, S. Takemura, G. Takigawa, N. Talbot, N.J. Tamagno, E. Tamburini, J. Tan, C.-P. Tan, L. Tan, M.L. Tan, M. Tan, Y.-J. Tanaka, K. Tanaka, M. Tang, D. Tang, D. Tang, G. Tanida, I. Tanji, K. Tannous, B.A. Tapia, J.A. Tasset-Cuevas, I. Tatar, M. Tavassoly, I. Tavernarakis, N. Taylor, A. Taylor, G.S. Taylor, G.A. Taylor, J.P. Taylor, M.J. Tchetina, E.V. Tee, A.R. Teixeira-Clerc, F. Telang, S. Tencomnao, T. Teng, B.-B. Teng, R.-J. Terro, F. Tettamanti, G. Theiss, A.L. Theron, A.E. Thomas, K.J. Thomé, M.P. Thomes, P.G. Thorburn, A. Thorner, J. Thum, T. Thumm, M. Thurston, T.L.M. Tian, L. Till, A. Ting, J.P.-Y. Ting, J.P.Y. Titorenko, V.I. Toker, L. Toldo, S. Tooze, S.A. Topisirovic, I. Torgersen, M.L. Torosantucci, L. Torriglia, A. Torrisi, M.R. Tournier, C. Towns, R. Trajkovic, V. Travassos, L.H. Triola, G. Tripathi, D.N. Trisciuoglio, D. Troncoso, R. Trougakos, I.P. Truttmann, A.C. Tsai, K.-J. Tschan, M.P. Tseng, Y.-H. Tsukuba, T. Tsung, A. Tsvetkov, A.S. Tu, S. Tuan, H.-Y. Tucci, M. Tumbarello, D.A. Turk, B. Turk, V. Turner, R.F.B. Tveita, A.A. Tyagi, S.C. Ubukata, M. Uchiyama, Y. Udelnow, A. Ueno, T. Umekawa, M. Umemiya-Shirafuji, R. Underwood, B.R. Ungermann, C. Ureshino, R.P. Ushioda, R. Uversky, V.N. Uzcátegui, N.L. Vaccari, T. Vaccaro, M.I. Váchová, L. Vakifahmetoglu-Norberg, H. Valdor, R. Valente, E.M. Vallette, F. Valverde, A.M. Van den Berghe, G. Van Den Bosch, L. van den Brink, G.R. van der Goot, F.G. van der Klei, I.J. van der Laan, L.J.W. van Doorn, W.G. van Egmond, M. van Golen, K.L. Van Kaer, L. Campagne, M.L. Vandenabeele, P. Vandenberghe, W. Vanhorebeek, I. Varela-Nieto, I. Vasconcelos, M.H. Vasko, R. Vavvas, D.G. Vega-Naredo, I. Velasco, G. Velentzas, A.D. Velentzas, P.D. Vellai, T. Vellenga, E. Vendelbo, M.H. Venkatachalam, K. Ventura, N. Ventura, S. Veras, P.S.T. Verdier, M. Vertessy, B.G. Viale, A. Vidal, M. Vieira, H.L.A. Vierstra, R.D. Vigneswaran, N. Vij, N. Vila, M. Villar, M. Villar, V.H. Villarroya, J. Vindis, C. Viola, G. Viscomi, M.T. Vitale, G. Vogl, D.T. Voitsekhovskaja, O.V. von Haefen, C. von Schwarzenberg, K. Voth, D.E. Vouret-Craviari, V. Vuori, K. Vyas, J.M. Waeber, C. Walker, C.L. Walker, M.J. Walter, J. Wan, L. Wan, X. Wang, B. Wang, C. Wang, C.-Y. Wang, C. Wang, C. Wang, C. Wang, D. Wang, F. Wang, F. Wang, G. Wang, H.-J. Wang, H. Wang, H.-G. Wang, H. Wang, H.-D. Wang, J. Wang, J. Wang, M. Wang, M.-Q. Wang, P.-Y. Wang, P. Wang, R.C. Wang, S. Wang, T.-F. Wang, X. Wang, X.-J. Wang, X.-W. Wang, X. Wang, X. Wang, Y. Wang, Y. Wang, Y. Wang, Y.-J. Wang, Y. Wang, Y. Wang, Y.T. Wang, Y. Wang, Z.-N. Wappner, P. Ward, C. Ward, D.M.V. Warnes, G. Watada, H. Watanabe, Y. Watase, K. Weaver, T.E. Weekes, C.D. Wei, J. Weide, T. Weihl, C.C. Weindl, G. Weis, S.N. Wen, L. Wen, X. Wen, Y. Westermann, B. Weyand, C.M. White, A.R. White, E. Whitton, J.L. Whitworth, A.J. Wiels, J. Wild, F. Wildenberg, M.E. Wileman, T. Wilkinson, D.S. Wilkinson, S. Willbold, D. Williams, C. Williams, K. Williamson, P.R. Winklhofer, K.F. Witkin, S.S. Wohlgemuth, S.E. Wollert, T. Wolvetang, E.J. Wong, E. Wong, G.W. Wong, R.W. Wong, V.K.W. Woodcock, E.A. Wright, K.L. Wu, C. Wu, D. Wu, G.S. Wu, J. Wu, J. Wu, M. Wu, M. Wu, S. Wu, W.K.K. Wu, Y. Wu, Z. Xavier, C.P.R. Xavier, R.J. Xia, G.-X. Xia, T. Xia, W. Xia, Y. Xiao, H. Xiao, J. Xiao, S. Xiao, W. Xie, C.-M. Xie, Z. Xie, Z. Xilouri, M. Xiong, Y. Xu, C. Xu, C. Xu, F. Xu, H. Xu, H. Xu, J. Xu, J. Xu, J. Xu, L. Xu, X. Xu, Y. Xu, Y. Xu, Z.-X. Xu, Z. Xue, Y. Yamada, T. Yamamoto, A. Yamanaka, K. Yamashina, S. Yamashiro, S. Yan, B. Yan, B. Yan, X. Yan, Z. Yanagi, Y. Yang, D.-S. Yang, J.-M. Yang, L. Yang, M. Yang, P.-M. Yang, P. Yang, Q. Yang, W. Yang, W.Y. Yang, X. Yang, Y. Yang, Y. Yang, Z. Yang, Z. Yao, M.-C. Yao, P.J. Yao, X. Yao, Z. Yao, Z. Yasui, L.S. Ye, M. Yedvobnick, B. Yeganeh, B. Yeh, E.S. Yeyati, P.L. Yi, F. Yi, L. Yin, X.-M. Yip, C.K. Yoo, Y.-M. Yoo, Y.H. Yoon, S.-Y. Yoshida, K.-I. Yoshimori, T. Young, K.H. Yu, H. Yu, J.J. Yu, J.-T. Yu, J. Yu, L. Yu, W.H. Yu, X.-F. Yu, Z. Yuan, J. Yuan, Z.-M. Yue, B.Y.J.T. Yue, J. Yue, Z. Zacks, D.N. Zacksenhaus, E. Zaffaroni, N. Zaglia, T. Zakeri, Z. Zecchini, V. Zeng, J. Zeng, M. Zeng, Q. Zervos, A.S. Zhang, D.D. Zhang, F. Zhang, G. Zhang, G.-C. Zhang, H. Zhang, H. Zhang, H. Zhang, J. Zhang, J. Zhang, J. Zhang, J.-P. Zhang, L. Zhang, L. Zhang, L. Zhang, M.-Y. Zhang, X. Zhang, X.D. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhao, M. Zhao, W.-L. Zhao, X. Zhao, Y.G. Zhao, Y. Zhao, Y. Zhao, Y.-X. Zhao, Z. Zhao, Z.J. Zheng, D. Zheng, X.-L. Zheng, X. Zhivotovsky, B. Zhong, Q. Zhou, G.-Z. Zhou, G. Zhou, H. Zhou, S.-F. Zhou, X.-J. Zhu, H. Zhu, H. Zhu, W.-G. Zhu, W. Zhu, X.-F. Zhu, Y. Zhuang, S.-M. Zhuang, X. Ziparo, E. Zois, C.E. Zoladek, T. Zong, W.-X. Zorzano, A. Zughaier, S.M.

Published
2016

28. Propagation of Localized Bending Deformations in Microtubules

Author

J.M. Dixon, Jack A. Tuszynski, M. Nishino, Stéphanie Portet, and L.-Y. Yu-Lee

Subjects
Computational Mathematics, Materials science, Microtubule, General Materials Science, General Chemistry, Bending, Electrical and Electronic Engineering, Composite material, Condensed Matter Physics
Published
2009
Full Text
View/download PDF

29. Concept of Single Duct Structure in Saddle System

Author

S. Tamai, M. Kato, M. Nishino, and Y. Yamahana

Subjects
Physics, General Materials Science, Geometry, Duct (flow), Saddle
Abstract

東北新幹線（八戸・新青森間）の三内丸山架道橋は橋長450m最大スパン150mのエクストラドーズドPC橋である。本橋梁では，主塔側の斜材定着に1重管構造の貫通固定方式のサドル定着を採用した。1重管構造は，鋼管の付着抵抗力，および鋼管に取り付けたアンカーフランジの引抜き抵抗力により，主塔コンクリートに固定させるものである。採用にあたっては，その性能が明確でないため実物大模型による載荷試験を行い性能を確認した。本報告では，設計計画から性能確認試験，および実橋への適用について報告する。

Published
2009
Full Text
View/download PDF

30. Introduction of a Base-Model for Eddy Current Testing of Printed Circuit Boards

Author

Sotoshi Yamada, Masayoshi Iwahara, M. Nishino, and H. Bayani

Subjects
Eddy current testing (ECT), Printed circuit board (PCB) inspection, FEM, Computer science, Physics::Instrumentation and Detectors, Mechanical engineering, Image processing, Finite-element method (FEM), Signal, Finite element method, Magnetic flux, Electronic, Optical and Magnetic Materials, Magnetic field, Meander coil, Printed circuit board, Electromagnetic coil, Eddy-current testing, PCB inspection, Eddy current testing, Electrical and Electronic Engineering, Smoothing
Abstract

In this paper we propose a model to reproduce a PCS pattern eddy current testing signal based on 3D FEM package and scanning simulation. In this method we consider some common PCB elements as test pieces while a simple Meander-type coil is utilized as excitation coil above the elements. Numerical solution to the above problem with the help of a 3D FEM provides the magnetic flux density in the region above the PCB test elements. Shifting the test element's position step by step and repeating the numerical calculation for each of the test elements new positions, the scanning process of a PCB test piece is simulated. Analysing and smoothing the magnetic field data from all of the aforementioned steps provide the final PCB pattern signal. Image processing technique was applied to obtain the PCB part image., Special Issue on 16th MAGADA Conference

Published
2008

32. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

Author

Lars Holmberg, J E Sadler, A. Srivastava, Christine A. Lee, Ian R. Peake, M. Nishino, Emmanuel J. Favaloro, Augusto B. Federici, Dominique Meyer, U. Budde, P. M. Mannucci, F. Rodeghiero, Zaverio M. Ruggeri, Jørgen Ingerslev, Jeroen Eikenboom, Reinhard Schneppenheim, Frank Hill, Robert R. Montgomery, David Lillicrap, William L. Nichols, and Claudine Mazurier

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, ADAMTS13 Protein, Review, Gene mutation, Platelet membrane glycoprotein, Models, Biological, Von Willebrand factor, hemic and lymphatic diseases, Internal medicine, von Willebrand Factor, Von Willebrand disease, Humans, Medicine, Clinical significance, Vwf multimers, biology, business.industry, Hematology, medicine.disease, Phenotype, Pathophysiology, Protein Structure, Tertiary, ADAM Proteins, von Willebrand Diseases, Endocrinology, Immunology, biology.protein, business, circulatory and respiratory physiology
Abstract

von Willebrand disease (VWD) is reportedly the most common bleeding disorder and is caused by deficiencies and/or defects in the adhesive plasma protein von Willebrand factor (VWF). Functionally, normal VWF prevents bleeding by promoting both primary and secondary haemostasis. In respect to primary haemostasis, VWF binds to both platelets and sub-endothelial matrix components, especially collagen, to anchor platelets to damaged vascular tissue and promote thrombus formation. VWF also stabilises and protects factor VIII in the circulation, delivering FVIII to the site of injury, which then facilitates secondary haemostasis and fibrin formation/thrombus stabilisation. As a result of this, patients with VWD suffer a bleeding diathesis reflective of a primary defect caused by defective/deficient VWF, which in some patients is compounded by a reduction in FVIII. Management of VWD, therefore, chiefly entails replacement of VWF, and sometimes also FVIII, to protect against bleeding. The current report principally focuses on the future potential for “personalised” management of VWD, given the emerging options in recombinant therapies. Recombinant VWF has been developed and is undergoing clinical trials, and this promising therapy may soon change the way in which VWD is managed. In particular, we can envisage a personalised treatment approach using recombinant VWF, with or without recombinant FVIII, depending on the type of VWD, the extent of deficiencies, and the period and duration of treatment.

Published
2006
Full Text
View/download PDF

33. Nonlinear analysis and damage monitoring of a one-sided patch repair with delamination

Author

Takahira Aoki and M. Nishino

Subjects
Timoshenko beam theory, Surface (mathematics), Engineering, business.industry, Delamination, Structural engineering, Computer Science::Numerical Analysis, Finite element method, Nonlinear system, Exact solutions in general relativity, One sided, Ceramics and Composites, Large deflection, business, Civil and Structural Engineering
Abstract

A simple analytical model using beam theory is developed to study a one-sided patch structure with delamination, considering the effect of large deflection and thermal stress. The method is based on the concept of equivalent delamination, which is analytically defined and employed to describe delay in load transfer between patch and parent plate with eccentrically aligned neutral axes. The analytical model has closed form solutions and good agreement with nonlinear finite element analysis (FEA) as well as experimental results is shown. The relation between the delamination propagation and the strains at monitoring locations is derived and feasibility of delamination monitoring based on surface strains is analytically demonstrated.

Published
2006
Full Text
View/download PDF

34. MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC

Author

F. Skoulidis, L. Albacker, M. Hellmann, M. Awad, J. Gainor, M. Goldberg, A. Schrock, L. Gay, J. Elvin, J. Ross, H. Rizvi, B. Carter, J. Erasmus, D. Halpenny, A. Plodkowski, N. Long, M. Nishino-Habatu, W. Denning, J. Rodriguez-Canales, P. Villalobos, E. Parra Cuentas, L. Sholl, J. Sauter, Y. Elamin, J. Zhang, G. Leonardi, K. Wong, P.J. Stephens, V. Papadimitrakopoulou, I. Wistuba, J. Wolchok, A. Shaw, P. Jänne, C. Rudin, V. Miller, and J. Heymach

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, biology, business.industry, Mutant, STK11, medicine.disease_cause, Blockade, Endocrinology, Oncology, PD-L1, Internal medicine, Cancer research, biology.protein, Medicine, KRAS, business, Loss function
Published
2017
Full Text
View/download PDF

35. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease

Author

Masayuki Onaka, Mutsuzo Takada, M Nishino, Yoshihiko Sakurai, and Hideo Takatsuka

Subjects
Male, Immunology, Mucocutaneous Lymph Node Syndrome, Thrombomodulin, Fibrinogen, hemic and lymphatic diseases, medicine, Immunology and Allergy, Humans, Endothelium, Endothelial dysfunction, Child, Blood Coagulation, Blood coagulation test, Retrospective Studies, Prothrombin time, medicine.diagnostic_test, business.industry, Endothelial Cells, Immunoglobulins, Intravenous, Infant, General Medicine, medicine.disease, Coagulation, Child, Preschool, Kawasaki disease, Female, Blood Coagulation Tests, Inflammation Mediators, business, medicine.drug, Partial thromboplastin time
Abstract

Background: Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. Although endothelial cell damage associated with vasculitis might lead to the hypercoagulability that is involved in coronary artery disease, the changes in coagulation after intravenous immunoglobulin therapy (IVIG) have not been well investigated in KD. The aims of this study were to address the changes in coagulation before and after IVIG in KD, and to further elucidate the coagulation-inflammation axis, with special attention to endothelial damage. Methods: We retrospectively collected the laboratory data before and after IVIG in 26 pediatric KD patients treated at the Nara Prefecture Western Medical Center between May 2010 and April 2012. Prothrombin time (PT), activated partial thromboplastin time (APTT) and levels of fibrin/fibrinogen degradation products (FDP) and D-dimer were assessed as coagulation markers. Fibrinogen, ferritin, serum amyloid A, procalcitonin and urine F2 microglobulin were assessed as inflammation markers. Thrombomodulin, antithrombin, factor VIII activity (FVIII:C), and von Willebrand factor antigen (VWF:Ag) were used to assess endothelial damage. Results: Prolonged PT and APTT before IVIG were significantly shortened after IVIG, and elevated levels of FDP and D-dimer were significantly decreased. Elevated levels of inflammation markers had decreased significantly after IVIG, but levels of FVIII:C and VWF:Ag remained high, even after IVIG. Conclusions: Ameliorated inflammation by IVIG might improve the hypercoagulable state. Nevertheless, our results suggest that endothelial damage might be prolonged in IVIG-treated patients. Control of endothelial damage in KD is critical. i 2014 S. Karger AG, Basel

Published
2014

36. Anomalous pressure dependence of the Curie temperature in MnRhP

Author

M. Nishino, Shoichi Endo, T. Kanomata, F. Ono, and N. Fujii

Subjects
Physics, Condensed matter physics, Exchange interaction, Intermetallic, General Physics and Astronomy, Curie temperature, Curie constant, Pressure dependence
Abstract

AC-susceptibility measurements were made in Fe2P-type intermetallic compound MnRhP under high pressures ranging from 1 to 10 GPa. The Curie temperature increased almost linearly with pressure. The average increasing rate was as large as 12 K/GPa. The exchange interaction in c-plane was found to be responsible for the large increasing rate.

Published
2000
Full Text
View/download PDF

37. 3-D PTV measurement on turbulence modification due to an oil droplet in a plane Couette water flow

Author

M. Nishino, S. Sakamoto, Yoshimichi Hagiwara, and Mitsuru Tanaka

Subjects
Physics, K-epsilon turbulence model, Turbulence, business.industry, Water flow, Mechanics, Condensed Matter Physics, Secondary flow, Physics::Fluid Dynamics, Transverse plane, Optics, Particle tracking velocimetry, Turbulence kinetic energy, Electrical and Electronic Engineering, business, Couette flow
Abstract

Three-dimensional particle tracking velocimetry (3-D PTV) measurements with a two-camera system have been conducted for a turbulent water plane Couette flow with an oil droplet in order to understand the modification of shear-dominant turbulence by the droplet. The parameters of the stereogrammetry, which are crucial for calculating the spatial coordinate of tracer particles from 2-D images of two cameras, have been determined with a careful calibration. The experimental results show that the axial and wall-normal turbulence intensities and the turbulent kinetic energy are enhanced locally in the confluence regions where axial main flow over the interface meets the secondary flow along the interface in the wall-normal direction. The secondary flows were observed only around the equator of the droplet. The wall-normal and transverse turbulence intensities are found to increase in the region above the droplet. This is due to the change in the direction of the primary flow over the top of the droplet. The turbulence in the other region is attenuated mainly because of the attenuation of the generation and evolution of the coherent structure in the neighbourhood of the droplet.

Published
2000
Full Text
View/download PDF

38. [Untitled]

Author

M Nishino

Subjects
Genetics, Inheritance (object-oriented programming), business.industry, Von Willebrand disease, medicine, medicine.disease, business
Published
2000
Full Text
View/download PDF

39. Granular-type giant magnetoresistance of Co–Ag and FeCo–CoAg films deposited with tandem method

Author

Shigeo Honda, H. Yamane, Masahiko Nawate, and M Nishino

Subjects
Magnetization, Nuclear magnetic resonance, Materials science, Ferromagnetism, Magnetoresistance, Annealing (metallurgy), Electrical resistivity and conductivity, Exchange interaction, Analytical chemistry, Giant magnetoresistance, Condensed Matter Physics, Electronic, Optical and Magnetic Materials, Superparamagnetism
Abstract

Co/Ag and FeCo/CoAg multilayers have been prepared on glass substrates and their magnetoresistance (MR) has been examined for applications as a magnetic sensor in a high field region. In these films, the giant MR occurs from the superparamagnetic Co granules in Ag or CoAg layers. On annealing, the MR ratio increases owing to the decrease in resistivity, and also the full-width of the half-maximum in the MR curve decreases relating to the magnetization becoming weaker. These changes in the physical properties come from the growth of Co granules and the enhancement of the exchange interaction between the Co granules and the adjacent ferromagnetic layers. Thus, the large MR ratio and sensitivity have been obtained by annealing at around 350–400°C, suggesting its use for a magnetic sensor in a high field region.

Published
1999
Full Text
View/download PDF

40. Nω-Phosphoarginine Phosphatase from Rat Renal Microsome Was Alkaline Phosphatase

Author

S. Tsujimura, Masako Kuba, M. Nishino, and Akira Kumon

Subjects
Male, Hydrolases, Detergents, Phosphatase, Tetramisole, Biophysics, Glucose-6-Phosphate, Arginine, Kidney, Biochemistry, Substrate Specificity, chemistry.chemical_compound, Organophosphorus Compounds, Column chromatography, Microsomes, Enzyme Stability, medicine, Animals, Sulfhydryl Compounds, Rats, Wistar, Sodium dodecyl sulfate, Tartrates, Molecular Biology, Gel electrophoresis, Chromatography, Chemistry, Glucosephosphates, Phosphoamidase, Alkaline Phosphatase, Phosphoric Monoester Hydrolases, Rats, medicine.anatomical_structure, Metals, Glucose-6-Phosphatase, Microsomes, Liver, Microsome, Alkaline phosphatase
Abstract

Activity hydrolyzing both N omega-phosphoarginine and glucose-6-phosphate was detected in rat renal microsome but not in hepatic microsome. Renal microsome was solubilized with 1% n-octyl-beta-D-thioglucoside and purified with DEAE-Sepharose column chromatography. Fractions hydrolyzing both N omega-phosphoarginine or glucose-6-phosphate were subjected to 7.5%-polyacrylamide gel electrophoresis in the presence of 0.1% sodium dodecyl sulfate. Phosphatase activity in the gels was detected by a lead nitrate stain using N omega-phosphoarginine or glucose-6-phosphate as substrates. Both substrates produced a stain in the region of the gel corresponding to a protein with a mass of 150 kDa. Extracts of slices from this region of the gel also hydrolyzed phosphocreatine, inorganic pyrophosphate, and O-phosphotyrosine. Moreover, the phosphatase had its optimal pH in the alkaline range and was inhibited completely by 20 microM sodium vanadate, 1 mM cysteine, and 1 mM tetramisole. All these properties indicate that the microsomal phosphoamidase (EC 3.9.1.1) of rat kidney was identical with alkaline phosphatase (EC 3.1.3.1).

Published
1994
Full Text
View/download PDF

41. Evaluation of | χ(3) | at the GTA of biexcitons in CuCl by high resolution polarization spectroscopy

Author

M. Hasuo, Nobukata Nagasawa, and M. Nishino

Subjects
Chemistry, business.industry, Biophysics, Analytical chemistry, High resolution, General Chemistry, Condensed Matter Physics, Polarization (waves), Biochemistry, Atomic and Molecular Physics, and Optics, Optics, Spectroscopy, business, Biexciton, Excitation
Abstract

High resolution polarization rotation spectroscopy is performed to evaluate the third-order nonlinear susceptibility, | χ (3) |, associated with the giant two-photon absorption (GTA) of biexcitons in CuCl. The true width of the biexciton at K ≈ 0 and | χ (3) | at the resonant peak are obtained to be 24 ± 2 μeV and (3.0 ± 0.9) × 10 -4 esu at the weakest excitation density of ⩽ 1 kW/cm 2 for a high quality crystal, respectively.

Published
1994
Full Text
View/download PDF

42. Emulsification Superiority of Super GumTM

Author

T. Katayama, T. Inoue, Glyn O. Phillips, T. Ido, and M. Nishino

Subjects
food.ingredient, food, Chemistry, Arabic, language, Stabiliser, Gum arabic, Food science, Natural gum, language.human_language
Abstract

Gum arabic is widely used as a natural emulsifier/stabiliser in oil-in-water emulsions for foods, especially in beverages. However, the emulsifying capacity of natural gum arabic is greatly influenced by a number of factors such as origin, producing area, age of the tree, climate changes during the harvest year, and storage conditions. These factors affect the composition and molecular weight of the gum arabic. Stability of concentrated emulsions greatly fluctuates depending on the molecular weight and arabinogalactan protein (AGP) content of the gum arabic utilised. Therefore, it is very difficult to constantly produce stable concentrated emulsions using natural gum arabic.

Published
2011
Full Text
View/download PDF

43. Effect of AGP on Emulsifying Stability of Gum Arabic

Author

Makoto Sakata, M. Nishino, Glyn O. Phillips, T. Katayama, and Saphwan Al-Assaf

Subjects
Gel permeation chromatography, Chromatography, Production area, food.ingredient, food, Arabic, Chemistry, Emulsion, language, Gum arabic, language.human_language, Natural gum, Laser light scattering
Abstract

Gum arabic (Acacia senegal) is an important natural oil-in-water emulsifier, which is widely used in the food industry. However, emulsification performance of natural gum arabic greatly varies depending on origin, production area, tree age, the weather and changes in arabinogalactan protein (AGP) content during storage. The correlation between AGP components and emulsifying stability has been studied in detail using natural gum arabic. Molecular weight and AGP content were analysed using GPC-MALLS (Gel permeation chromatography – multi-angle laser light scattering) and emulsifying stability was evaluated by measuring the particle size of test emulsions after accelerated storage. AGP content of natural gum arabic varies greatly. Gum arabic with a higher AGP content has a higher emulsifying stability, whereas gum arabic with a lower AGP content has a lower emulsifying stability. It is very important for emulsion users to have access to a supply of high performance natural gum arabic with a higher and consistent AGP content.

Published
2011
Full Text
View/download PDF

44. Development of trimming technology for hot rolled ultra-low carbon steel

Author

M. Nishino, J. Ikeda, and Y. Matsuda

Subjects
Engineering, Carbon steel, business.industry, Metallurgy, Metals and Alloys, Scrap, engineering.material, Condensed Matter Physics, Hot rolled, Pickling, Materials Chemistry, Trimming, Development (differential geometry), Physical and Theoretical Chemistry, Trimmer, business
Abstract

Ultra-low carbon steel is so soft that it is hard to get satisfactory trimmed face. In cold rolling after trimming, it causes saw-toothed cracks (saw-edge). To solve this problem, we have developed new technology with applying the roll to push up trimmed scrap for top knife of the trimmer. Applying this technology to our pickling line (No. 2 CPL Kashima Steel Works, Sumitomo Metal Ind., Ltd.), we could have restrained the saw-edge.

Published
1993
Full Text
View/download PDF

45. Clinical Evaluation of Spontaneous Echo Contrast and Thrombus in the Left Ventricle by Transesophageal Echocardiography during Cardiac Assist

Author

M. Nishino, T. Ito, M. Yasuno, Takenobu Kamada, T. Kuryu, S. Hasegawa, Masatsugu Hori, H. Abe, and Y. Yamada

Subjects
medicine.medical_specialty, E/A ratio, business.industry, General Medicine, Blood flow, medicine.disease, Thrombosis, medicine.anatomical_structure, Ventricle, Internal medicine, medicine, Cardiology, Cardiac assist, Radiology, Esophagus, Thrombus, business, Clinical evaluation
Published
1993
Full Text
View/download PDF

46. Progression of carotid atherosclerosis in Japanese patients with coronary artery disease

Author

M Nishino, Kenji Sueyoshi, M Ishida, H Tanaka, and Ryuzo Fukunaga

Subjects
Carotid Artery Diseases, medicine.medical_specialty, Coronary Disease, Constriction, Pathologic, Coronary Angiography, Constriction, Coronary artery disease, Japan, Internal medicine, medicine, Humans, Stroke, Coronary atherosclerosis, Ultrasonography, Advanced and Specialized Nursing, medicine.diagnostic_test, Vascular disease, business.industry, Incidence (epidemiology), Intracranial Arteriosclerosis, medicine.disease, Cerebral Angiography, Cardiology, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, Complication, Cerebral angiography
Abstract

Along with the recent changes in lifestyle in Japan, the incidence of coronary artery disease has increased while the incidence of stroke appears to be decreasing. We investigated the relation between the progression of carotid atherosclerosis and the severity of coronary artery disease in the Japanese population. The 2-year change in extracranial carotid atherosclerosis in 50 Japanese patients who underwent coronary angiography was evaluated using carotid echotomography. To quantify the extent of carotid atherosclerosis, the maximal thickness measurements of all plaques were summed for an individual plaque score, except for new plaques found on reexamination. Carotid disease progression was evaluated by the sum of plaque score change and the thickness of the new plaque found on reexamination. The plaque score changed by -3.2 to 10.1 mm (mean +/- SD, 1.06 +/- 2.42 mm). The extent of coronary atherosclerosis (p less than 0.02) and serum total cholesterol level (p less than 0.01) were different between the progressing (n = 17) and the nonprogressing (n = 30) groups of carotid atherosclerosis when the progressing group included the patients with a delta plaque score of greater than or equal to 1.0 mm. Neither age, serum triglyceride level, serum high-density lipoprotein cholesterol level, pack-years of smoking, percentage of smokers, percentage of hypertensive patients, nor percentage of diabetic patients was different between the two groups. Carotid disease progression was significantly higher in patients with three-vessel coronary disease than in patients without significant coronary artery disease (p less than 0.005). There was a significant positive linear correlation between carotid disease progression and Gensini's coronary artery disease score (R = 0.411, p less than 0.005). Our data showed that severe coronary artery disease and a high serum total cholesterol level were strong predictors for carotid disease progression in Japanese patients with high rates of coronary artery disease.

Published
1992
Full Text
View/download PDF

48. Processing and Characterization of Recombinant von Willebrand Factor Expressed in Different Cell Types Using a Vaccinia Virus Vector

Author

Claudine Mazurier, Sylvie Jorieux, Dominique Meyer, P. Meulien, Michael Courtney, M. Nishino, Geneviève Piétu, A. Pavirani, Karin Dott, D. Oufkir, and Jean-Pierre Girma

Subjects
Gel electrophoresis, Chinese hamster ovary cell, Chicken Cells, Hematology, Biology, Molecular biology, law.invention, Antigen, law, hemic and lymphatic diseases, Complementary DNA, Baby hamster kidney cell, Recombinant DNA, Intracellular
Abstract

SummaryThe cloning of the cDNA encoding von Willebrand factor (vWF) has revealed that it is synthesized as a large precursor (pre-pro-vWF) molecule and it is now clear that the prosequence or vWAgll is responsible for the intracellular multimerization of vWF. We have cloned the complete vWF cDNA and expressed it using a recombinant vaccinia virus as vector. We have characterized the structure and function of the recombinant vWF (rvWF) secreted from five different cell types: baby hamster kidney (BHK), Chinese hamster ovary (CHO), human fibroblasts (143B), mouse fibroblasts (L) and primary embryonic chicken cells. Forty-eight hours after infection, the quantity of vWF antigen found in the cell supernatant varied from 3 to 12 U/dl depending on the cell type. By SDS-agarose gel electrophoresis, the percentage of high molecular weight forms of vWF varied from 39 to 49% relative to normal plasma for BHK, CHO, 143B and chicken cells but was less than 10% for L cells. In all cell types, the two anodic subbands of each multimer were missing. The two cathodic subbands were easily detected only in BHK and L cells. By SDS-PAGE of reduced samples, pro-vWF was present in similar quantity to the fully processed vWF subunit in L cells, present in moderate amounts in BHK and CHO and in very low amounts in 143B and chicken cells. rvWF from all cells bound to collagen and to platelets in the presence of ristocetin, the latter showing a high correlation between binding efficiency and degree of multimerization. rvWF from all cells was also shown to bind to purified FVIII and in this case binding appeared to be independent of the degree of multimerization. We conclude that whereas vWF is naturally synthesized only by endothelial cells and megakaryocytes, it can be expressed in a biologically active form from various other cell types.

Published
1992
Full Text
View/download PDF

49. von Willebrand Disease: Diagnosis and Treatment

Author

M Nishino

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, biology, business.industry, Mucocutaneous bleeding, medicine.disease, Dermatology, Thrombosis, Von Willebrand factor, hemic and lymphatic diseases, Epidemiology, medicine, biology.protein, Von Willebrand disease, business
Abstract

von Willebrand disease (VWD) is caused by quantitative or qualitative defects of von Willebrand factor (VWF), associated with mucocutaneous bleeding symptoms. VWD is classified into three major groups and four subcategories. The classification is intended to be simple, to rely on widely available laboratory tests, and to correlate with important clinical characteristics. It is meant to facilitate the diagnosis, treatment, and counseling of patients with VWD. The International Society on Thrombosis and Haemostasis/Scientific and Standardization Committee (ISTH/SSC) reviewed the classification and published update information on the diagnosis and treatment of VWD in 2006 based on the most recent pathophysiology data for VWF. Notably, Vicenza type has been classified into type 1 from type 2M. In epidemiology, there may be small differences of frequency in VWD subcategories (type 2) between Europe and lapan. For treatment, factor VIII/VWF concentrate is commonly employed in Japan, although DDAVP has been the first choice for VWD in Europe.

Published
2009
Full Text
View/download PDF

50. Factor VIII Binding Ability of von Willebrand Factor in Several Fractions of Normal Plasma and Plasma from Several Types of von Willebrand Disease

Author

M Nishino, Hiromu Fukui, Akira Yoshioka, Masakuni Yamamoto, Toshiya Nishikubo, and Shuji Miura

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, biology, Chemistry, Size-exclusion chromatography, medicine.disease, Molecular biology, Binding ability, Von Willebrand factor, hemic and lymphatic diseases, Cryoprecipitate, cardiovascular system, Von Willebrand disease, medicine, biology.protein, Normal range, circulatory and respiratory physiology
Abstract

Binding ability of plasma von Willebrand factor (vWF) to purified factor VIII (F. VIII) in normal subjects and patients with von Willebrand disease (vWD Type IIA, IIB, IIC) was analysed in a solid phase assay. A vWF fraction, mainly containing large multimer-vWF, was obtained from gel filtration of cryoprecipitate, whereas another vWF fraction, containing small multimer-vWF, as cryo-supernatant. Binding ability of vWF in small and large multimer-vWF fractions was identical. Binding ability of vWF in the plasmas from vWD Type IIA, IIB and IIC was found to be within normal range. These results suggested that the vWF binding to F. VIII was independent from multimeric structure.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results